{"gene":"RPS6KA3","run_date":"2026-06-10T07:46:27","timeline":{"discoveries":[{"year":1996,"finding":"RSK2 (pp90RSK family) was purified, sequenced, and biochemically characterized as CREB kinase — the kinase that phosphorylates CREB at Ser-133 in response to growth factor-stimulated RAS-MAPK signaling, thereby coupling the RAS-MAPK pathway to immediate early gene transcription.","method":"Protein purification, sequencing, in vitro kinase assay, in vivo phosphorylation assay","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 / Strong — biochemical purification, sequencing, in vitro and in vivo kinase assays; replicated in multiple subsequent studies","pmids":["8688081"],"is_preprint":false},{"year":1996,"finding":"Mutations in RSK2 (Rsk-2 gene) cause Coffin-Lowry syndrome; missense mutations affecting sites critical for RSK2 function render the protein inactive in S6 kinase assays, establishing loss of kinase activity as the disease mechanism.","method":"Mutation screening, in vitro S6 kinase activity assay","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct enzymatic assay of mutant proteins, replicated across many subsequent mutation studies","pmids":["8955270"],"is_preprint":false},{"year":1998,"finding":"RSK2 activity is specifically required for EGF-induced CREB Ser-133 phosphorylation and c-fos gene induction; CLS fibroblasts lacking functional RSK2 show dramatically attenuated EGF-stimulated CREB phosphorylation and c-fos expression, restored by wild-type RSK2 re-expression.","method":"Loss-of-function in CLS patient fibroblasts, transfection rescue, in vivo phosphorylation assay, reporter assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (patient cells, rescue, reporter assay), replicated by other labs","pmids":["9770464"],"is_preprint":false},{"year":1999,"finding":"RSK2 is required for EGF-stimulated phosphorylation of histone H3; CLS patient fibroblasts and RSK2-knockout mouse ES cells fail to exhibit EGF-stimulated H3 phosphorylation, while mitotic H3 phosphorylation is unaffected; re-introduction of wild-type RSK2 restores EGF-stimulated H3 phosphorylation.","method":"Loss-of-function (CLS patient cells and homologous recombination knockout ES cells), rescue by wild-type RSK2 transfection","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout and patient-cell loss-of-function with rescue experiment, replicated independently","pmids":["10436156"],"is_preprint":false},{"year":1999,"finding":"RSK2 (pp90rsk2) is identical to Fos kinase, which phosphorylates c-Fos at Ser-362 in a RAS/MEK-dependent manner; purified Fos kinase from NGF-stimulated PC12 cells was identified as pp90rsk2 by mass spectrometry and shown to be the same as NGFI-B kinase I. CREB kinase was distinguished as a distinct species from pp90rsk2.","method":"Affinity purification, mass spectrometry, in vitro kinase assay, chromatographic comparison","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — protein purification plus mass spectrometry identification plus kinase assays in a single rigorous study","pmids":["9920881"],"is_preprint":false},{"year":2000,"finding":"Phosphorylation of RSK2 at Ser386 in the hydrophobic motif (by the C-terminal kinase domain) creates a phosphoserine-dependent docking site that recruits PDK1, which then phosphorylates RSK2 at Ser227 (activating the N-terminal kinase domain); a S386K mutant showed no PDK1 interaction or Ser227 phosphorylation; a synthetic pSer386 peptide activated PDK1 6-fold in vitro.","method":"Co-immunoprecipitation, mutagenesis, in vitro kinase assay with synthetic peptide, in vivo phosphorylation assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted in vitro activation, mutagenesis, and in vivo validation in a single study","pmids":["10856237"],"is_preprint":false},{"year":2000,"finding":"Xenopus Rsk2 is the predominant p90Rsk isozyme (~120 nM) in oocytes/eggs, forms a heteromeric complex with p42 MAP kinase via sequences at the extreme C-terminus of Rsk2, and can be activated in vitro by p42 MAP kinase to a specific activity comparable to maximal in vivo activation.","method":"Protein quantification, co-immunoprecipitation, peptide competition, in vitro kinase reconstitution","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted in vitro activation and mechanistic domain mapping by peptide competition","pmids":["10934212"],"is_preprint":false},{"year":2001,"finding":"RSK2 and CBP form a complex in quiescent cells in which both RSK2 kinase activity and CBP HAT activity are inhibited; mitogenic stimulation causes dissociation dependent on RSK2 Ser227 phosphorylation, releasing both kinase and acetyltransferase activities.","method":"Co-immunoprecipitation, kinase activity assay, HAT activity assay, mutagenesis (Ser227)","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP, activity assays, and mutagenesis in a single study","pmids":["11564891"],"is_preprint":false},{"year":2002,"finding":"RSK2 directly phosphorylates Bad at Ser112 in vitro, and RSK2-deficient CLS cells are defective for UVB-induced Bad Ser112 phosphorylation; phosphorylation of Bad at Ser112 by RSK2 (and JNK1/MSK1) promotes dissociation of Bad from Bcl-XL.","method":"In vitro kinase assay with active RSK2, RSK2-deficient CLS cells, dominant-negative mutants, co-immunoprecipitation (Bad/Bcl-XL)","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay and genetic loss-of-function with mechanistic readout","pmids":["11983683"],"is_preprint":false},{"year":2003,"finding":"PEA-15 binds directly to RSK2 (but not RSK1) via the C-terminus of PEA-15, co-precipitates in cells, blocks RSK2 nuclear accumulation after EGF stimulation, inhibits RSK2 kinase activity by ~50%, and suppresses RSK2-dependent CREB transcription and histone H3 phosphorylation.","method":"Co-immunoprecipitation from cells, in vitro pulldown with purified PEA-15 and in vitro translated RSK2, kinase assay, reporter assay, nuclear localization assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP, direct in vitro binding, kinase assay, functional reporter and localization studies in one report","pmids":["12796492"],"is_preprint":false},{"year":2004,"finding":"ATF4 is a direct substrate of RSK2; RSK2 phosphorylates ATF4 and is required for timely osteoblast differentiation, terminal osteoblast differentiation, osteoblast-specific gene expression, and posttranscriptional regulation of Type I collagen synthesis. ATF4 deficiency recapitulates the skeletal phenotype of CLS.","method":"In vitro kinase assay, genetic knockout mice (RSK2 and ATF4), osteoblast differentiation assays, gene expression analysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro kinase assay plus two genetic knockouts with convergent phenotypes, published in Cell","pmids":["15109498"],"is_preprint":false},{"year":2005,"finding":"RSK2 phosphorylates c-Fos at Ser362, stabilizing c-Fos protein; loss of RSK2 leads to reduced c-Fos levels, decreased proliferation, and increased apoptosis of transformed osteoblasts, impairing c-Fos-dependent osteosarcoma formation in mice.","method":"RSK2 knockout mice, c-Fos phosphorylation site mutagenesis, osteosarcoma formation assay, apoptosis and proliferation assays","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic knockout with defined cellular phenotype and mutagenesis of phosphorylation site","pmids":["15719069"],"is_preprint":false},{"year":2007,"finding":"FGFR3 directly tyrosine-phosphorylates RSK2 at Y529, facilitating binding of inactive ERK to RSK2, which is required for ERK-dependent phosphorylation and activation of RSK2; inhibition of RSK2 by siRNA or FMK induces apoptosis in FGFR3-expressing t(4;14)-positive myeloma cells.","method":"Phospho-proteomics, in vitro kinase assay (FGFR3 + RSK2), co-immunoprecipitation, siRNA knockdown, apoptosis assay","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 1 / Moderate — phosphoproteomic identification, in vitro kinase assay, mechanistic co-IP, genetic KD with phenotype","pmids":["17785202"],"is_preprint":false},{"year":2007,"finding":"RSK2 directly interacts with NFAT3 (via both N- and C-terminal kinase domains binding to NLS1/Ser-Pro/polyproline domains of NFAT3), phosphorylates NFAT3 in vitro (Km=3.559 μM), induces NFAT3 nuclear localization upon stimulation, and is required for skeletal muscle cell differentiation into myotubes.","method":"Co-immunoprecipitation, in vitro kinase assay, RSK2-/- cells, siRNA knockdown, myotube differentiation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with Km determination, genetic knockout, and siRNA with mechanistic phenotype","pmids":["17213202"],"is_preprint":false},{"year":2007,"finding":"PEA-15 acts as a scaffold that independently binds ERK and RSK2, increases ERK-RSK2 association in a concentration-dependent manner, enhances RSK2 activity and CREB-mediated transcription, and this scaffolding function is regulated by PEA-15 phosphorylation. PEA-15-null lymphocytes show impaired RSK2 activation rescued by exogenous PEA-15.","method":"Co-immunoprecipitation, kinase activity assay, reporter assay, PEA-15 knockout lymphocytes, rescue by exogenous PEA-15","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods including KO cells with rescue and mechanistic binding studies","pmids":["18077417"],"is_preprint":false},{"year":2007,"finding":"EGF-stimulated RSK2 tyrosine phosphorylation at Tyr-529 is mediated by Src family kinases (Src and Fyn), not by EGFR directly; Src/Fyn phosphorylation of Y529 facilitates binding of inactive ERK to RSK2, required for ERK-dependent RSK2 activation; PP2 (Src inhibitor) attenuates EGF-dependent RSK2 activation and Y529 phosphorylation.","method":"Mass spectrometry identification, in vitro kinase assay (Src/Fyn + recombinant RSK2), GST-RSK2 reconstitution, mutagenesis (Y529F), Src inhibitor PP2","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with recombinant proteins, mass spectrometry, mutagenesis, and reconstitution","pmids":["18156174"],"is_preprint":false},{"year":2008,"finding":"RSK2 colocalizes with TIA-1 and PABP1 in stress granules in stressed cells; the RSK2 N-terminal kinase domain directly interacts with the prion-related domain of TIA-1; RSK2 sequestration in granules and TIA-1 sequestration are codependent. Upon mitogen stimulation, RSK2 is released from stress granules and translocates to the nucleus via a C-terminal nucleocytoplasmic shuttling sequence, dependent on TIA-1; nuclear RSK2 alone is sufficient to induce cyclin D1 and enhance proliferation.","method":"Colocalization (fluorescence microscopy), co-immunoprecipitation, domain mapping, siRNA knockdown, nuclear localization assay, cyclin D1 reporter","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods: colocalization, reciprocal co-IP, domain mapping, siRNA, and functional nuclear-localization experiment","pmids":["18775331"],"is_preprint":false},{"year":2008,"finding":"RSK2 physically interacts with and phosphorylates PLD1 at Thr-147 in the phox homology domain; expression of inactive RSK2 mutants or RSK2 knockdown dramatically impairs exocytotic response in chromaffin cells; phosphomimetic PLD1-T147 mutant fully restores secretion in RSK2-depleted cells, placing RSK2 upstream of PLD1 in calcium-regulated exocytosis.","method":"Co-immunoprecipitation, in vitro kinase assay, dominant-negative mutants, siRNA knockdown, phosphomimetic rescue, chromaffin cell exocytosis assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay, genetic loss-of-function with phosphomimetic rescue establishing RSK2→PLD1 Thr147 pathway","pmids":["18550821"],"is_preprint":false},{"year":2009,"finding":"FGFR3 interacts with RSK2 through residue W332 in the RSK2 linker region; this interaction is required for FGFR3-dependent phosphorylation of RSK2 at Y529 and Y707. Phosphorylation at Y707 contributes to RSK2 activation by disrupting the autoinhibitory αL-helix, while Y529 phosphorylation facilitates ERK binding.","method":"Co-immunoprecipitation, mutagenesis (W332, Y529, Y707), in vitro kinase assay, murine bone marrow transplant with RSK2-knockout cells","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis of multiple sites, in vitro kinase assay, and in vivo genetic model","pmids":["19223461"],"is_preprint":false},{"year":2009,"finding":"The RSK2 N-terminal kinase domain (NTD) is required for activation of the ERK-mediated C-terminal kinase domain (CTD); NTD plays a key role in substrate phosphorylation; Val82 and Lys100 in the NTD are critical for kaempferol binding and RSK2 activity, established by homology modeling, mutagenesis, and small-molecule docking.","method":"Mutagenesis (Val82, Lys100), homology model + docking validated by mutagenesis, kinase activity assay, domain deletion experiments","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — mutagenesis and kinase assays with computational validation, single lab","pmids":["19435896"],"is_preprint":false},{"year":2010,"finding":"RSK2 phosphorylates caspase-8 at Thr-263, promoting caspase-8 ubiquitination and proteasomal degradation in response to EGF; RSK2 thereby blocks Fas-induced apoptosis through phosphorylation of caspase-8.","method":"In vitro kinase assay, site-directed mutagenesis (Thr263), proteasome inhibition assay, Fas-induced apoptosis assay, RSK2 knockout cells","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro kinase assay and mutagenesis, single lab","pmids":["21183680"],"is_preprint":false},{"year":2010,"finding":"ATF1 is a novel substrate of RSK2; RSK2 phosphorylates ATF1 at Ser-63, enhancing ATF1 transcriptional activity; eriodictyol binds the RSK2 NTD (confirmed by crystal structure docking and in vitro pulldown) and inhibits RSK2-mediated ATF1 phosphorylation.","method":"In vitro kinase assay, crystal structure-based docking, in vitro pulldown, cell-based phosphorylation assay, reporter assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro kinase assay with structural docking and pulldown confirmation, single lab","pmids":["21098035"],"is_preprint":false},{"year":2011,"finding":"RSK2 directly phosphorylates histone H2AX at both Ser139 and a newly identified site Ser16; EGF-induced phosphorylation at both sites is decreased in RSK2 knockout cells; RSK2-mediated H2AX phosphorylation enhances H2AX stability and prevents EGF-induced cell transformation; RSK2 and DNA-PK (but not ATM/ATR) are required for Ser139 phosphorylation, while only RSK2 is required for Ser16 phosphorylation.","method":"In vitro kinase assay, RSK2 knockout cells, co-immunoprecipitation, immunofluorescence, cell transformation assay","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro kinase assay and knockout cells, single lab","pmids":["21224359"],"is_preprint":false},{"year":2012,"finding":"RSK2 mediates Ras/Raf-dependent inactivation of integrins: active RSK2 impairs cell adhesion and fibronectin matrix assembly, promotes cell motility, reduces actin stress fibers, disrupts focal adhesions, co-localizes with the integrin activator talin, promotes filamin phosphorylation and integrin binding, and is itself activated in response to fibronectin ligation.","method":"RSK2 siRNA knockdown, integrin activation assays, co-localization by immunofluorescence, fibronectin matrix assembly assay, migration assay, co-immunoprecipitation","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — multiple functional assays and co-localization in single lab","pmids":["23118220"],"is_preprint":false},{"year":2013,"finding":"RSK2 phosphorylates PLD1 at Thr-147, activating PLD1 and promoting synthesis of phosphatidic acid at sites of neurite outgrowth; this RSK2→PLD1 pathway controls TiVAMP/VAMP-7 vesicle fusion and is required for NGF-induced neurite outgrowth; phosphomimetic PLD1 rescues neurite outgrowth in RSK2-silenced cells.","method":"RSK2 and PLD1 knockout mice neurons, siRNA, pharmacological inhibition, TIRF microscopy, phosphomimetic rescue in PC12 cells","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic knockout neuronal model, pharmacological inhibition, TIRF microscopy, and phosphomimetic rescue with multiple orthogonal methods","pmids":["24336713"],"is_preprint":false},{"year":2013,"finding":"RSK2-CREB signaling upregulates fascin-1 expression; RSK2 knockdown disrupts filopodia formation and bundling in invasive cancer cells; fascin-1 expression rescues the loss of invasion caused by RSK2 knockdown, establishing the RSK2→CREB→Fascin-1 axis in cancer cell invasion and metastasis.","method":"siRNA knockdown, RSK2 inhibitor (FMK-MEA), fascin-1 rescue expression, filopodia imaging, invasion assay, in vivo metastasis model","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — mechanistic rescue experiment with functional pathway placement, single lab","pmids":["24085294"],"is_preprint":false},{"year":2013,"finding":"RSK2 directly binds and phosphorylates stathmin at Ser16 at the leading edge of cancer cells, reducing stathmin-mediated microtubule depolymerization and promoting microtubule stability; phosphomimetic stathmin-S16D rescues the decreased invasive and metastatic potential caused by RSK2 knockdown.","method":"Co-immunoprecipitation, in vitro kinase assay, RSK2 siRNA knockdown, phosphomimetic rescue, invasion and metastasis assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — in vitro kinase assay, co-IP, and phosphomimetic rescue, single lab","pmids":["27041561"],"is_preprint":false},{"year":2013,"finding":"RSK2 inhibits apoptosis signal-regulating kinase 1 (ASK1) by phosphorylating Ser83, Thr1109, and Thr1326; phospho-T1109/T1326 inhibits ATP binding to ASK1, and phospho-S83 attenuates ASK1 substrate MKK6 binding; RSK2 also provides antianoikis protection via CREB-mediated upregulation of PTK6 and downregulation of ING3.","method":"In vitro kinase assay, mutagenesis, ATP-binding assay, substrate binding assay, RSK2 knockdown, anoikis assay, gene expression analysis","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro kinase assay with mechanistic site mutagenesis, single lab","pmids":["23608533"],"is_preprint":false},{"year":2013,"finding":"RSK2 phosphorylates TRAF6 at Ser46, Ser47, and Ser48; this phosphorylation is required for TRAF6 K63 ubiquitination, which promotes downstream inflammation signaling (IKKα/β, p38, JNK); RSK2 knockout mice show reduced F4/80 and CD3 infiltration and reduced TRAF6 K63 ubiquitination in colon tissue.","method":"In vitro kinase assay, RSK2 knockout mice, co-immunoprecipitation, ubiquitination assay, colon inflammation model","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 1–2 / Weak — in vitro kinase assay and genetic KO with in vivo readout, single lab","pmids":["29563609"],"is_preprint":false},{"year":2013,"finding":"RSK2 interacts with FGFR1, confirmed by yeast two-hybrid and in vitro/in vivo experiments; phosphorylated RSK2 phosphorylates Ser789 in the C-terminal tail of FGFR1; RSK2 inhibition leads to prolonged FGFR1 tyrosine transphosphorylation; mutation of Ser789 to Ala or RSK2 inhibition reduces FGFR1 endocytosis and ubiquitination, explaining prolonged signaling.","method":"Yeast two-hybrid, co-immunoprecipitation, in vitro kinase assay, site-directed mutagenesis (S789A), FGFR1 endocytosis assay, ubiquitination assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay, mutagenesis, and functional endocytosis assays with multiple orthogonal approaches in one study","pmids":["24141780"],"is_preprint":false},{"year":2015,"finding":"RSK2 (but not RSK1) directly interacts with and phosphorylates NHE3 at Ser663 at the apical membrane domain, mediating LPA-induced NHE3 stimulation; Pyk2 maintains PDK1 autophosphorylation required for RSK2 activation upstream of NHE3.","method":"RSK2-specific siRNA knockdown, co-immunoprecipitation at apical membrane, in vitro phosphorylation assay, Ser663 mutagenesis, NHE3 transport activity assay","journal":"American journal of physiology. Cell physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — co-IP, mutagenesis, and transport assay in single lab","pmids":["25855080"],"is_preprint":false},{"year":2016,"finding":"β-Trcp ubiquitin ligase and RSK2 cooperate to degrade FOXN2; RSK2 phosphorylates FOXN2 at Ser365 and Ser369 in a conserved DSGYAS motif, targeting it for β-Trcp-mediated ubiquitination and proteasomal degradation, which promotes tumor growth and radioresistance in lung cancer.","method":"Co-immunoprecipitation, in vitro kinase assay, site-directed mutagenesis (Ser365, Ser369), ubiquitination assay, gain/loss-of-function studies","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro kinase assay and mutagenesis with functional readout, single lab","pmids":["29396548"],"is_preprint":false},{"year":2017,"finding":"RSK2 directly interacts with leukemia-associated RhoGEF (LARG) and nucleotide-bound Rho isoforms (RhoA, RhoB, RhoC but not Rac1 or Cdc42); EGF/FBS stimulation induces association of endogenous RSK2 with LARG; RSK2 phosphorylates LARG at Ser1288 to activate RhoA; Thr577 phosphorylation on RSK2 is essential for this; RSK2-mediated motility requires RhoA and RhoB but not RhoC.","method":"Co-immunoprecipitation (endogenous), in vitro kinase assay, mutagenesis (Ser1288, Thr577), RhoA activity assay, migration/invasion assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Moderate — endogenous co-IP, in vitro kinase assay, multiple mutagenesis experiments, and functional motility assays","pmids":["29279389"],"is_preprint":false},{"year":2018,"finding":"RSK2 phosphorylates the regulatory myosin light chain (RLC20) at Ser19 in vitro, promoting smooth muscle contractility; RSK2 also phosphorylates an activating site on NHE-1, causing cytosolic alkalinization and increased intracellular Ca2+ that promotes vasoconstriction; Rsk2-deficient mice show dilated resistance arteries, reduced myogenic tone, reduced RLC20 phosphorylation, suppressed NHE-1 activity, and lower blood pressure.","method":"In vitro kinase assay (RSK2 + RLC20), Rsk2 knockout mice (myogenic tone, blood pressure, pH and Ca2+ measurements), in situ phosphorylation analysis","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay identifying Ser19, multiple physiological readouts in genetic knockout mice","pmids":["30377223"],"is_preprint":false},{"year":2018,"finding":"ERα physically interacts with RSK2 through its N-terminus and sequesters active RSK2 into the nucleus, where it activates a proneoplastic transcriptional network; antiestrogens disrupt the RSK2–ERα interaction, driving RSK2 into the cytoplasm; transgenic mice with stable nuclear RSK2 in the mammary gland develop high-grade ductal carcinoma in situ.","method":"Co-immunoprecipitation, nuclear fractionation, transgenic mouse model, in vitro and in vivo breast cancer models","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP, fractionation, transgenic mouse model, multiple in vitro and in vivo models in single study","pmids":["29351904"],"is_preprint":false},{"year":2019,"finding":"RSK2 directly interacts with ELK3 through its N-terminal kinase and linker domains binding to the D and C domains of ELK3, phosphorylates ELK3, and enhances c-fos promoter activity via ELK3; RSK2 deficiency reduces ELK3 nuclear localization.","method":"Co-immunoprecipitation (domain mapping), kinase assay, reporter assay (c-fos promoter), immunocytofluorescence, RSK2 knockdown/knockout","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — co-IP with domain mapping and functional reporter, single lab","pmids":["31018569"],"is_preprint":false},{"year":2020,"finding":"RSK2-inactivating mutations in HCC attenuate a SOS1/2-dependent negative feedback loop, leading to activation of MAPK signaling; restoring RSK2 expression in RSK2-null HCC cells suppresses proliferation and migration in vitro and tumorigenicity in vivo.","method":"Exome sequencing, RSK2 re-expression in natural RSK2-null cells, RNA-seq, qRT-PCR, mass spectrometry, xenograft tumor model","journal":"Journal of hepatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (RNA-seq, MS, in vitro and in vivo functional assays), single lab","pmids":["32918955"],"is_preprint":false},{"year":2020,"finding":"RSK2 directly binds AMPKα2 in the nucleus and phosphorylates it at Thr172, promoting autophagy under ER stress; IRE1α (ER membrane UPR sensor) is required for ERK1/2-RSK2 activation under ER stress; suppression of RSK2-mediated autophagy enhances sensitivity to ER stress-inducing agents.","method":"Co-immunoprecipitation, in vitro kinase assay (RSK2 + AMPKα2), IRE1α knockdown, RSK2 knockdown, autophagy assay, in vivo xenograft","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — co-IP and in vitro kinase assay, single lab","pmids":["32958832"],"is_preprint":false},{"year":2020,"finding":"TGF-β activates ERK and RSK2, causing nuclear translocation of phosphorylated RSK2, which then phosphorylates VGLL1 at Ser84; phosphorylated VGLL1 acts as a transcription cofactor of TEAD4, activating MMP9 transcription to promote gastric cancer malignancy.","method":"Site-directed mutagenesis (Ser84), co-immunoprecipitation, EMSA, ChIP assay, immunoprecipitation, reporter assay","journal":"Biochimica et biophysica acta. Molecular cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — mutagenesis, co-IP, ChIP, and functional assays, single lab","pmids":["33069758"],"is_preprint":false},{"year":2022,"finding":"GDH1 (phosphorylated by EGFR at Tyr135) and RSK2 cooperate to enhance CREB activity via CaMKIV signaling, promoting lung cancer metastasis; co-targeting RSK2 and GDH1 synergistically attenuates cancer cell invasion, anoikis resistance, and immune escape.","method":"siRNA knockdown, pharmacological inhibition, kinase assay, invasion/anoikis assay, CD8 T cell infiltration analysis, patient tumor correlation","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — functional genetic and pharmacological experiments with pathway mechanistic readouts, single lab","pmids":["36516759"],"is_preprint":false},{"year":2023,"finding":"RSK2 controls RPS6 phosphorylation in neurons, which is essential for peripheral and central nervous system axon regeneration; RSK2 controls the peripheral nerve preconditioning effect; the RSK2-RPS6 axis drives CNS regeneration in the dorsal column, synaptic plasticity, and target innervation leading to functional recovery.","method":"RSK2 knockout mice, in vivo axon injury/regeneration assay, DRG neuron culture, adeno-associated virus shRNA knockdown, electrophysiology","journal":"PLoS biology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — genetic knockout with defined in vivo phenotype, single lab","pmids":["37068088"],"is_preprint":false},{"year":2012,"finding":"RSK2 functions in the medial habenula to contribute to acute morphine analgesia; RSK2 knockout reduces acute morphine analgesia in the tail immersion test; AAV-mediated RSK2 knockdown specifically in the habenula recapitulates the reduced analgesia, suggesting a mu opioid receptor-RSK2 signaling mechanism in this brain region.","method":"RSK2 knockout mice, AAV-mediated shRNA knockdown in habenula, tail immersion test","journal":"Neuropsychopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout confirmed by region-specific knockdown with convergent phenotype","pmids":["22218090"],"is_preprint":false},{"year":2009,"finding":"RSK2 knockdown in cells enhances influenza virus polymerase activity and viral growth; RSK2 knockdown reduces NF-κB- and IFN-β-dependent promoter stimulation in response to influenza; RSK2 knockdown suppresses influenza-induced PKR phosphorylation, placing RSK2 upstream of PKR in the innate antiviral response.","method":"siRNA knockdown, viral polymerase activity assay, reporter assays (NF-κB, IFN-β), PKR phosphorylation assay","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — siRNA knockdown with multiple functional readouts, single lab","pmids":["19129453"],"is_preprint":false},{"year":2003,"finding":"RSK2-deficient cells are defective for UV-induced STAT3 Ser727 phosphorylation, restored by ectopic RSK2 re-expression; active RSK2 induces phosphorylation of STAT3 immunoprecipitates in vitro, requiring a cofactor or downstream kinase; ATM is required upstream for UVA-stimulated RSK2 activation.","method":"RSK2-deficient cells, rescue by ectopic RSK2 expression, in vitro kinase assay on STAT3 immunoprecipitates, dominant-negative STAT3-β, reporter assay","journal":"The Journal of biological chemistry","confidence":"Low","confidence_rationale":"Tier 3 / Weak — indirect in vitro phosphorylation (requires cofactor, not direct reconstitution), single lab","pmids":["12562765"],"is_preprint":false},{"year":2010,"finding":"RSK2 interacts with and phosphorylates GSK3β at Ser9, inhibiting GSK3β activity; RSK2-deficient MEFs show reduced GSK3β Ser9 phosphorylation upon EGF and calcium ionophore stimulation.","method":"Co-immunoprecipitation, in vitro kinase assay, RSK2 knockout MEFs, rescue by RSK2 re-expression","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single co-IP plus rescue, single lab","pmids":["24055036"],"is_preprint":false},{"year":2014,"finding":"RSK2 deficiency in TNF-α transgenic mice results in earlier and exacerbated arthritis with increased inflammatory cytokine production, MMP activity, and osteoclastogenic molecules; bone marrow from RSK2-null mice fails to transfer this phenotype, indicating RSK2 expression in mesenchymal (synovial fibroblast) cells controls synoviocyte hyperplasia and the course of arthritis.","method":"RSK2 knockout in TNFtg arthritis model, bone marrow transplant, in vitro FLS characterization, gene expression profiling","journal":"Annals of the rheumatic diseases","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout crossed with disease model plus bone marrow transplant experiment to identify cell-type specificity","pmids":["25414238"],"is_preprint":false},{"year":2010,"finding":"RSK2 knockdown in cortical radial precursors (by shRNA in vitro and in utero electroporation in vivo) decreases neurogenesis and increases the proportion of proliferating Pax6-positive radial precursor cells, establishing that RSK2 is required for cortical radial precursors to differentiate into neurons (but is not required for astrocyte generation).","method":"shRNA knockdown in primary cortical precursors, in utero electroporation, immunostaining for neuronal and progenitor markers","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo and in vitro genetic loss-of-function with distinct cellular phenotype","pmids":["20832397"],"is_preprint":false}],"current_model":"RSK2 (RPS6KA3) is a dual-kinase-domain serine/threonine kinase activated downstream of ERK/MAPK: ERK phosphorylates the C-terminal kinase domain, which autophosphorylates Ser386 to create a PDK1-docking site, whereupon PDK1 phosphorylates Ser227 in the N-terminal kinase domain (the substrate-phosphorylating domain); Src/Fyn-mediated tyrosine phosphorylation at Y529 (and FGFR3 at Y707) additionally facilitates ERK recruitment; activated RSK2 phosphorylates a broad array of substrates including CREB (Ser133), histone H3, ATF4, ATF1, c-Fos (Ser362), ELK3, Bad (Ser112), caspase-8 (Thr263), H2AX (Ser16/Ser139), NFAT3, GSK3β (Ser9), ASK1 (Ser83/Thr1109/Thr1326), PLD1 (Thr147), stathmin (Ser16), LARG (Ser1288), TRAF6 (Ser46/47/48), NHE3 (Ser663), RLC20 (Ser19), AMPKα2 (Thr172), VGLL1 (Ser84), FGFR1 (Ser789), and FOXN2 (Ser365/369); it shuttles between cytoplasm (where it associates with TIA-1 in stress granules and with PEA-15 as a scaffold for ERK) and nucleus (where ERα can sequester it for transcriptional programs); through these substrates RSK2 controls gene transcription, chromatin remodeling, cell survival/apoptosis, exocytosis, integrin signaling, actin/microtubule dynamics, smooth muscle contractility, osteoblast differentiation, neurogenesis, and axon regeneration, and its loss-of-function causes Coffin-Lowry syndrome."},"narrative":{"mechanistic_narrative":"RSK2 (RPS6KA3) is a serine/threonine kinase that couples the RAS–MAPK cascade to gene transcription, chromatin remodeling, cell survival, and cytoskeletal dynamics, originally identified as the growth factor-stimulated CREB kinase that phosphorylates CREB at Ser133 to drive immediate-early gene transcription [PMID:8688081, PMID:9770464]. Its activation is governed by a multi-step, dual-kinase-domain mechanism: the C-terminal kinase domain phosphorylates Ser386 to create a phosphoserine docking site that recruits and activates PDK1, which in turn phosphorylates Ser227 in the substrate-active N-terminal kinase domain [PMID:10856237], while the N-terminal domain is itself required for activation of the ERK-controlled C-terminal domain [PMID:19435896]; in oocytes RSK2 forms a heteromeric complex with p42 MAP kinase through its extreme C-terminus and is directly activatable by MAP kinase in vitro [PMID:10934212]. Receptor tyrosine kinase and Src-family input tunes this circuit, as Src/Fyn phosphorylate Tyr529 and FGFR3 phosphorylates Tyr529/Tyr707 to facilitate ERK recruitment and relieve autoinhibition [PMID:18156174, PMID:19223461]. Through a broad substrate repertoire, RSK2 phosphorylates transcriptional and chromatin effectors (CREB, histone H3, c-Fos Ser362, ATF4) to control immediate-early transcription, c-Fos stability, osteoblast differentiation, and chromatin remodeling [PMID:10436156, PMID:9920881, PMID:15109498, PMID:15719069], promotes cell survival by phosphorylating Bad (Ser112), caspase-8 (Thr263), and ASK1 to block apoptosis and anoikis [PMID:11983683, PMID:21183680, PMID:23608533], and regulates cytoskeletal and membrane dynamics by phosphorylating PLD1 (Thr147) for exocytosis and neurite outgrowth, stathmin (Ser16) and the RhoGEF LARG (Ser1288) for cell motility, and RLC20 (Ser19) with NHE-1 for smooth muscle contractility and blood pressure control [PMID:18550821, PMID:24336713, PMID:27041561, PMID:29279389, PMID:30377223]. RSK2 localization is dynamically controlled: it is sequestered in cytoplasmic stress granules via TIA-1 binding and released upon mitogen stimulation to shuttle into the nucleus where it drives cyclin D1 and proliferation, a function modulated by the scaffold PEA-15 and by ERα-mediated nuclear retention [PMID:18775331, PMID:18077417, PMID:29351904]. Loss-of-function mutations in RSK2 that abolish its kinase activity cause Coffin-Lowry syndrome [PMID:8955270].","teleology":[{"year":1996,"claim":"Establishing RSK2's core function and disease relevance: it was defined as the growth factor-activated CREB kinase that links RAS-MAPK signaling to transcription, and concurrently shown to cause Coffin-Lowry syndrome through loss of kinase activity.","evidence":"Protein purification, sequencing, and in vitro/in vivo kinase assays; mutation screening with S6 kinase activity assay of mutant proteins","pmids":["8688081","8955270"],"confidence":"High","gaps":["Did not resolve the upstream activation steps beyond MAPK","Did not establish which substrates mediate the disease phenotype"]},{"year":1998,"claim":"Patient-cell loss-of-function with rescue confirmed RSK2 is specifically required for EGF-induced CREB Ser133 phosphorylation and c-fos induction, tying the kinase to a defined transcriptional output.","evidence":"CLS patient fibroblast loss-of-function, transfection rescue, in vivo phosphorylation and reporter assays","pmids":["9770464"],"confidence":"High","gaps":["Did not address other RSK2-dependent transcription factors","Did not map the activation hierarchy"]},{"year":1999,"claim":"Genetic knockout and patient-cell studies extended RSK2's reach to chromatin, showing it mediates EGF-stimulated (but not mitotic) histone H3 phosphorylation, and identified it as the c-Fos kinase phosphorylating Ser362.","evidence":"CLS patient cells and knockout ES cells with rescue; affinity purification, mass spectrometry, and in vitro kinase assays","pmids":["10436156","9920881"],"confidence":"High","gaps":["Did not establish whether H3 phosphorylation is direct or via an intermediate kinase","Did not resolve overlap between CREB kinase and Fos kinase identities"]},{"year":2000,"claim":"Reconstituted biochemistry solved the activation mechanism: Ser386 phosphorylation creates a PDK1 docking site driving Ser227 phosphorylation, and RSK2 forms a stable MAP kinase complex via its C-terminus.","evidence":"Co-IP, mutagenesis, in vitro kinase assays with synthetic phosphopeptide, peptide competition, and in vitro reconstitution","pmids":["10856237","10934212"],"confidence":"High","gaps":["Did not address tyrosine-phosphorylation inputs","Did not resolve the role of the N-terminal domain in CTD activation"]},{"year":2001,"claim":"RSK2 activity was coupled to coactivator control, showing it forms a mutually inhibitory complex with CBP that dissociates upon Ser227-dependent activation to release both kinase and HAT activities.","evidence":"Reciprocal co-IP, kinase and HAT activity assays, Ser227 mutagenesis","pmids":["11564891"],"confidence":"High","gaps":["Did not define the binding interface","Did not establish in vivo transcriptional consequences"]},{"year":2003,"claim":"Identification of PEA-15 as a direct, RSK2-selective binding partner revealed spatial regulation: it blocks RSK2 nuclear accumulation and dampens its kinase and transcriptional output.","evidence":"Co-IP, in vitro pulldown, kinase, reporter, and nuclear localization assays","pmids":["12796492"],"confidence":"High","gaps":["Did not yet establish the scaffolding mechanism on ERK","Did not address physiological relevance in tissues"]},{"year":2004,"claim":"Genetic dissection linked RSK2 to skeletal biology through ATF4 phosphorylation, explaining the CLS bone phenotype via osteoblast differentiation and collagen synthesis.","evidence":"In vitro kinase assay, RSK2 and ATF4 knockout mice, osteoblast differentiation and gene expression assays","pmids":["15109498"],"confidence":"High","gaps":["Did not map the ATF4 phosphosite","Did not address other skeletal substrates"]},{"year":2005,"claim":"RSK2 was shown to stabilize c-Fos via Ser362 phosphorylation, defining a pro-tumorigenic role in osteosarcoma cell survival and proliferation.","evidence":"RSK2 knockout mice, c-Fos phosphosite mutagenesis, osteosarcoma formation and apoptosis/proliferation assays","pmids":["15719069"],"confidence":"High","gaps":["Did not address human tumor relevance","Did not define degradation machinery for unphosphorylated c-Fos"]},{"year":2007,"claim":"Tyrosine-kinase inputs and scaffolding were defined: Src/Fyn and FGFR3 phosphorylate Tyr529 to promote ERK binding and RSK2 activation, and PEA-15 was shown to scaffold ERK-RSK2 association, while RSK2 was also placed in calcium signaling via NFAT3.","evidence":"Phosphoproteomics, in vitro kinase assays, co-IP, mutagenesis, Src inhibitor, knockout/knockdown cells, and rescue","pmids":["17785202","18156174","18077417","17213202"],"confidence":"High","gaps":["Did not establish the full structural basis of ERK recruitment","Did not resolve relative contributions of Src vs FGFR3 in different cell types"]},{"year":2008,"claim":"Subcellular trafficking was resolved: RSK2 is sequestered in stress granules through TIA-1 binding and released upon mitogen stimulation to enter the nucleus and drive cyclin D1 and proliferation; RSK2 was also linked to regulated exocytosis via PLD1 Thr147.","evidence":"Colocalization, co-IP, domain mapping, siRNA, nuclear localization and cyclin D1 reporter assays; in vitro kinase, phosphomimetic rescue in chromaffin cells","pmids":["18775331","18550821"],"confidence":"High","gaps":["Did not define the shuttling signal at residue level","Did not establish which nuclear substrates drive cyclin D1"]},{"year":2009,"claim":"FGFR3 docking and intramolecular activation logic were refined: FGFR3 binds the RSK2 linker (W332) to phosphorylate Tyr529/Tyr707, and the N-terminal domain was shown to be required for activation of the ERK-driven C-terminal domain.","evidence":"Co-IP, multi-site mutagenesis, in vitro kinase assay, bone marrow transplant; homology modeling/docking validated by mutagenesis","pmids":["19223461","19435896"],"confidence":"High","gaps":["NTD activation model rests on a single lab with computational validation","Did not resolve the autoinhibitory αL-helix structure experimentally"]},{"year":2011,"claim":"RSK2's anti-apoptotic and genome-protective substrate set expanded to caspase-8 (Thr263, promoting degradation) and histone H2AX (Ser16/Ser139, enhancing stability), implicating it in survival and transformation control.","evidence":"In vitro kinase assays, site mutagenesis, knockout cells, proteasome and apoptosis/transformation assays","pmids":["21183680","21224359"],"confidence":"Medium","gaps":["Each rests on single-lab evidence","Did not establish reciprocal regulation in tissue contexts"]},{"year":2013,"claim":"A coherent cytoskeletal/motility program emerged: RSK2 inactivates integrins, phosphorylates stathmin (Ser16) and LARG (Ser1288) to control microtubules and RhoA, drives PLD1-dependent neurite outgrowth, suppresses ASK1, and upregulates fascin-1 via CREB, while also phosphorylating FGFR1 (Ser789) to control receptor endocytosis.","evidence":"Co-IP, in vitro kinase assays, siRNA/knockout, phosphomimetic rescue, migration/invasion/endocytosis assays, knockout neuron models with TIRF","pmids":["23118220","24336713","24085294","27041561","23608533","24141780","29279389"],"confidence":"Medium","gaps":["Most substrate links derive from individual labs","Did not integrate competing motility substrates into one quantitative model"]},{"year":2018,"claim":"Physiological and oncogenic roles were extended in vivo: RSK2 drives smooth muscle contractility (RLC20 Ser19, NHE-1) and blood pressure, and ERα-mediated nuclear sequestration of RSK2 promotes a proneoplastic transcriptional network in breast tissue.","evidence":"In vitro kinase assay, Rsk2 knockout mice with physiological readouts; co-IP, fractionation, transgenic mouse breast cancer model","pmids":["30377223","29351904"],"confidence":"High","gaps":["ERα-RSK2 axis rests on a single study","Did not define the full nuclear transcriptional targets"]},{"year":2020,"claim":"RSK2 was placed in stress-response and feedback circuits: it phosphorylates AMPKα2 (Thr172) to promote ER-stress autophagy and VGLL1 (Ser84) to drive TEAD4/MMP9 transcription, while RSK2-inactivating mutations relieve SOS1/2 feedback to activate MAPK in liver cancer.","evidence":"Co-IP, in vitro kinase assays, knockdown, autophagy assays; ChIP/EMSA/reporter; exome sequencing, RNA-seq, MS, xenografts","pmids":["32958832","33069758","32918955"],"confidence":"Medium","gaps":["Context-dependent tumor-promoting vs tumor-suppressive roles remain unreconciled","Each mechanism rests on single-lab evidence"]},{"year":2023,"claim":"RSK2 was established as a driver of axon regeneration via control of RPS6 phosphorylation, completing a neuronal role spanning neurogenesis, opioid analgesia, and regeneration.","evidence":"RSK2 knockout mice, in vivo axon injury/regeneration assays, DRG culture, AAV shRNA, electrophysiology","pmids":["37068088"],"confidence":"Medium","gaps":["Did not define whether RPS6 phosphorylation is direct","Did not link the neuronal phenotype to CLS cognitive features"]},{"year":null,"claim":"How RSK2's broad substrate selection is spatially and temporally partitioned across competing transcriptional, survival, and cytoskeletal programs in a given cell remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying framework reconciling tumor-suppressive (HCC) versus oncogenic (breast, lung, gastric) roles","No structural model of the full activated dual-kinase-domain holoenzyme with bound partners","Substrate prioritization mechanisms under different stimuli are uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,5,8,10,17,26,32,33]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,5,8,17,27]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[5]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[3,22]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,4,35]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[9,16]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[9,16,34,37]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[23,30]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,5,15,18,32]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,2,4,10,38]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[8,20,27]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[3,22]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[37]}],"complexes":[],"partners":["PDK1","MAPK1","PEA15","TIA1","FGFR3","CREBBP","LARG","ESR1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P51812","full_name":"Ribosomal protein S6 kinase alpha-3","aliases":["90 kDa ribosomal protein S6 kinase 3","p90-RSK 3","p90RSK3","Insulin-stimulated protein kinase 1","ISPK-1","MAP kinase-activated protein kinase 1b","MAPK-activated protein kinase 1b","MAPKAP kinase 1b","MAPKAPK-1b","Ribosomal S6 kinase 2","RSK-2","pp90RSK2"],"length_aa":740,"mass_kda":83.7,"function":"Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of the transcription factors CREB1, ETV1/ER81 and NR4A1/NUR77, regulates translation through RPS6 and EIF4B phosphorylation, and mediates cellular proliferation, survival, and differentiation by modulating mTOR signaling and repressing pro-apoptotic function of BAD and DAPK1 (PubMed:16213824, PubMed:16223362, PubMed:17360704, PubMed:9770464). In fibroblast, is required for EGF-stimulated phosphorylation of CREB1 and histone H3 at 'Ser-10', which results in the subsequent transcriptional activation of several immediate-early genes (PubMed:10436156, PubMed:9770464). In response to mitogenic stimulation (EGF and PMA), phosphorylates and activates NR4A1/NUR77 and ETV1/ER81 transcription factors and the cofactor CREBBP (PubMed:16223362). Upon insulin-derived signal, acts indirectly on the transcription regulation of several genes by phosphorylating GSK3B at 'Ser-9' and inhibiting its activity (PubMed:8250835). Phosphorylates RPS6 in response to serum or EGF via an mTOR-independent mechanism and promotes translation initiation by facilitating assembly of the preinitiation complex (PubMed:17360704). In response to insulin, phosphorylates EIF4B, enhancing EIF4B affinity for the EIF3 complex and stimulating cap-dependent translation (PubMed:18508509, PubMed:18813292). Is involved in the mTOR nutrient-sensing pathway by directly phosphorylating TSC2 at 'Ser-1798', which potently inhibits TSC2 ability to suppress mTOR signaling, and mediates phosphorylation of RPTOR, which regulates mTORC1 activity and may promote rapamycin-sensitive signaling independently of the PI3K/AKT pathway (PubMed:18722121). Mediates cell survival by phosphorylating the pro-apoptotic proteins BAD and DAPK1 and suppressing their pro-apoptotic function (PubMed:16213824). Promotes the survival of hepatic stellate cells by phosphorylating CEBPB in response to the hepatotoxin carbon tetrachloride (CCl4) (PubMed:18508509, PubMed:18813292). Is involved in cell cycle regulation by phosphorylating the CDK inhibitor CDKN1B, which promotes CDKN1B association with 14-3-3 proteins and prevents its translocation to the nucleus and inhibition of G1 progression (By similarity). In LPS-stimulated dendritic cells, is involved in TLR4-induced macropinocytosis, and in myeloma cells, acts as effector of FGFR3-mediated transformation signaling, after direct phosphorylation at Tyr-529 by FGFR3 (By similarity). Negatively regulates EGF-induced MAPK1/3 phosphorylation via phosphorylation of SOS1 (By similarity). Phosphorylates SOS1 at 'Ser-1134' and 'Ser-1161' that create YWHAB and YWHAE binding sites and which contribute to the negative regulation of MAPK1/3 phosphorylation (By similarity). Phosphorylates EPHA2 at 'Ser-897', the RPS6KA-EPHA2 signaling pathway controls cell migration (PubMed:26158630). Acts as a regulator of osteoblast differentiation by mediating phosphorylation of ATF4, thereby promoting ATF4 transactivation activity (By similarity)","subcellular_location":"Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P51812/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/RPS6KA3","classification":"Not Classified","n_dependent_lines":34,"n_total_lines":1208,"dependency_fraction":0.028145695364238412},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000177189","cell_line_id":"CID001262","localizations":[{"compartment":"cytoplasmic","grade":3},{"compartment":"nucleoplasm","grade":3}],"interactors":[{"gene":"CSNK2B","stoichiometry":10.0},{"gene":"PDCD6IP","stoichiometry":4.0},{"gene":"ROCK2","stoichiometry":0.2},{"gene":"GRSF1","stoichiometry":0.2},{"gene":"RPS6KA1","stoichiometry":0.2},{"gene":"ARHGEF12","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001262","total_profiled":1310},"omim":[{"mim_id":"603434","title":"PROLIFERATION AND APOPTOSIS ADAPTOR PROTEIN 15; PEA15","url":"https://www.omim.org/entry/603434"},{"mim_id":"601685","title":"RIBOSOMAL PROTEIN S6 KINASE A2; RPS6KA2","url":"https://www.omim.org/entry/601685"},{"mim_id":"601684","title":"RIBOSOMAL PROTEIN S6 KINASE A1; RPS6KA1","url":"https://www.omim.org/entry/601684"},{"mim_id":"303600","title":"COFFIN-LOWRY SYNDROME; CLS","url":"https://www.omim.org/entry/303600"},{"mim_id":"300844","title":"INTELLECTUAL DEVELOPMENTAL DISORDER, X-LINKED 19; XLID19","url":"https://www.omim.org/entry/300844"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nucleoli","reliability":"Additional"},{"location":"Vesicles","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/RPS6KA3"},"hgnc":{"alias_symbol":["RSK2","HU-3"],"prev_symbol":["MRX19","CLS"]},"alphafold":{"accession":"P51812","domains":[{"cath_id":"3.30.200.20","chopping":"53-151_355-390","consensus_level":"medium","plddt":79.3617,"start":53,"end":390},{"cath_id":"1.10.510.10","chopping":"152-347","consensus_level":"medium","plddt":89.0245,"start":152,"end":347},{"cath_id":"3.30.200.20","chopping":"417-493","consensus_level":"high","plddt":88.0806,"start":417,"end":493},{"cath_id":"1.10.510.10","chopping":"500-720","consensus_level":"high","plddt":79.2168,"start":500,"end":720}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P51812","model_url":"https://alphafold.ebi.ac.uk/files/AF-P51812-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P51812-F1-predicted_aligned_error_v6.png","plddt_mean":76.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RPS6KA3","jax_strain_url":"https://www.jax.org/strain/search?query=RPS6KA3"},"sequence":{"accession":"P51812","fasta_url":"https://rest.uniprot.org/uniprotkb/P51812.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P51812/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P51812"}},"corpus_meta":[{"pmid":"8688081","id":"PMC_8688081","title":"Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase.","date":"1996","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8688081","citation_count":1076,"is_preprint":false},{"pmid":"15109498","id":"PMC_15109498","title":"ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome.","date":"2004","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/15109498","citation_count":656,"is_preprint":false},{"pmid":"10436156","id":"PMC_10436156","title":"Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation of histone H3.","date":"1999","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/10436156","citation_count":406,"is_preprint":false},{"pmid":"8955270","id":"PMC_8955270","title":"Mutations in the kinase Rsk-2 associated with Coffin-Lowry syndrome.","date":"1996","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8955270","citation_count":319,"is_preprint":false},{"pmid":"10856237","id":"PMC_10856237","title":"A phosphoserine-regulated docking site in the protein kinase RSK2 that recruits and activates PDK1.","date":"2000","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10856237","citation_count":262,"is_preprint":false},{"pmid":"9770464","id":"PMC_9770464","title":"Rsk-2 activity is necessary for epidermal growth factor-induced phosphorylation of CREB protein and transcription of c-fos gene.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9770464","citation_count":261,"is_preprint":false},{"pmid":"37794185","id":"PMC_37794185","title":"The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity.","date":"2023","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/37794185","citation_count":143,"is_preprint":false},{"pmid":"18775331","id":"PMC_18775331","title":"Codependent functions of RSK2 and the apoptosis-promoting factor TIA-1 in stress granule assembly and cell survival.","date":"2008","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/18775331","citation_count":131,"is_preprint":false},{"pmid":"17785202","id":"PMC_17785202","title":"FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway.","date":"2007","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/17785202","citation_count":127,"is_preprint":false},{"pmid":"2831944","id":"PMC_2831944","title":"Complete cDNA sequence of human complement Cls and close physical linkage of the homologous genes Cls and Clr.","date":"1987","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2831944","citation_count":111,"is_preprint":false},{"pmid":"2828323","id":"PMC_2828323","title":"Disruption of the Escherichia coli cls gene responsible for cardiolipin synthesis.","date":"1988","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/2828323","citation_count":108,"is_preprint":false},{"pmid":"11564891","id":"PMC_11564891","title":"Mitogen-regulated RSK2-CBP interaction controls their kinase and acetylase activities.","date":"2001","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11564891","citation_count":106,"is_preprint":false},{"pmid":"12393804","id":"PMC_12393804","title":"Expression analysis of RSK gene family members: the RSK2 gene, mutated in Coffin-Lowry syndrome, is prominently expressed in brain structures essential for cognitive function and learning.","date":"2002","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12393804","citation_count":92,"is_preprint":false},{"pmid":"11983683","id":"PMC_11983683","title":"Activation of JNK1, RSK2, and MSK1 is involved in serine 112 phosphorylation of Bad by ultraviolet B radiation.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11983683","citation_count":84,"is_preprint":false},{"pmid":"11180593","id":"PMC_11180593","title":"Mutations in the X-linked RSK2 gene (RPS6KA3) in patients with Coffin-Lowry syndrome.","date":"2001","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/11180593","citation_count":79,"is_preprint":false},{"pmid":"15719069","id":"PMC_15719069","title":"Essential role of RSK2 in c-Fos-dependent osteosarcoma development.","date":"2005","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/15719069","citation_count":76,"is_preprint":false},{"pmid":"9837815","id":"PMC_9837815","title":"Mutation analysis of the RSK2 gene in Coffin-Lowry patients: extensive allelic heterogeneity and a high rate of de novo mutations.","date":"1998","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9837815","citation_count":68,"is_preprint":false},{"pmid":"17213202","id":"PMC_17213202","title":"RSK2 mediates muscle cell differentiation through regulation of NFAT3.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17213202","citation_count":65,"is_preprint":false},{"pmid":"11500490","id":"PMC_11500490","title":"ERK2- and p90(Rsk2)-dependent pathways regulate the CCAAT/enhancer-binding protein-beta interaction with serum response factor.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11500490","citation_count":58,"is_preprint":false},{"pmid":"10553090","id":"PMC_10553090","title":"Salicylic acid and aspirin inhibit the activity of RSK2 kinase and repress RSK2-dependent transcription of cyclic AMP response element binding protein- and NF-kappa B-responsive genes.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10553090","citation_count":56,"is_preprint":false},{"pmid":"26253302","id":"PMC_26253302","title":"Magnolin inhibits cell migration and invasion by targeting the ERKs/RSK2 signaling pathway.","date":"2015","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26253302","citation_count":55,"is_preprint":false},{"pmid":"21098035","id":"PMC_21098035","title":"Eriodictyol inhibits RSK2-ATF1 signaling and suppresses EGF-induced neoplastic cell transformation.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21098035","citation_count":54,"is_preprint":false},{"pmid":"12796492","id":"PMC_12796492","title":"RSK2 activity is regulated by its interaction with PEA-15.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12796492","citation_count":54,"is_preprint":false},{"pmid":"19435896","id":"PMC_19435896","title":"A regulatory mechanism for RSK2 NH(2)-terminal kinase activity.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19435896","citation_count":53,"is_preprint":false},{"pmid":"24994661","id":"PMC_24994661","title":"Kaempferol targets RSK2 and MSK1 to suppress UV radiation-induced skin cancer.","date":"2014","source":"Cancer prevention research (Philadelphia, Pa.)","url":"https://pubmed.ncbi.nlm.nih.gov/24994661","citation_count":52,"is_preprint":false},{"pmid":"27535706","id":"PMC_27535706","title":"Melatonin Represses Metastasis in Her2-Postive Human Breast Cancer Cells by Suppressing RSK2 Expression.","date":"2016","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/27535706","citation_count":52,"is_preprint":false},{"pmid":"9712919","id":"PMC_9712919","title":"A protein kinase C-, Ras-, and RSK2-dependent signal transduction pathway activates the cAMP-responsive element-binding protein transcription factor following T cell receptor engagement.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9712919","citation_count":51,"is_preprint":false},{"pmid":"19223461","id":"PMC_19223461","title":"Fibroblast growth factor receptor 3 associates with and tyrosine phosphorylates p90 RSK2, leading to RSK2 activation that mediates hematopoietic transformation.","date":"2009","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19223461","citation_count":50,"is_preprint":false},{"pmid":"23447564","id":"PMC_23447564","title":"Direct targeting of MEK1/2 and RSK2 by silybin induces cell-cycle arrest and inhibits melanoma cell growth.","date":"2013","source":"Cancer prevention research (Philadelphia, Pa.)","url":"https://pubmed.ncbi.nlm.nih.gov/23447564","citation_count":47,"is_preprint":false},{"pmid":"24085294","id":"PMC_24085294","title":"The prometastatic ribosomal S6 kinase 2-cAMP response element-binding protein (RSK2-CREB) signaling pathway up-regulates the actin-binding protein fascin-1 to promote tumor metastasis.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24085294","citation_count":47,"is_preprint":false},{"pmid":"12562765","id":"PMC_12562765","title":"Ataxia telangiectasia mutated proteins, MAPKs, and RSK2 are involved in the phosphorylation of STAT3.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12562765","citation_count":47,"is_preprint":false},{"pmid":"23118220","id":"PMC_23118220","title":"RSK2 protein suppresses integrin activation and fibronectin matrix assembly and promotes cell migration.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23118220","citation_count":46,"is_preprint":false},{"pmid":"18077417","id":"PMC_18077417","title":"ERK MAP kinase is targeted to RSK2 by the phosphoprotein PEA-15.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18077417","citation_count":46,"is_preprint":false},{"pmid":"23551430","id":"PMC_23551430","title":"Luteolin suppresses UVB-induced photoageing by targeting JNK1 and p90 RSK2.","date":"2013","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23551430","citation_count":45,"is_preprint":false},{"pmid":"29396548","id":"PMC_29396548","title":"β-Trcp ubiquitin ligase and RSK2 kinase-mediated degradation of FOXN2 promotes tumorigenesis and radioresistance in lung cancer.","date":"2018","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/29396548","citation_count":44,"is_preprint":false},{"pmid":"21619683","id":"PMC_21619683","title":"Ribosomal protein S6 kinase (RSK)-2 as a central effector molecule in RON receptor tyrosine kinase mediated epithelial to mesenchymal transition induced by macrophage-stimulating protein.","date":"2011","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21619683","citation_count":43,"is_preprint":false},{"pmid":"32918955","id":"PMC_32918955","title":"RSK2-inactivating mutations potentiate MAPK signaling and support cholesterol metabolism in hepatocellular carcinoma.","date":"2020","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/32918955","citation_count":42,"is_preprint":false},{"pmid":"18550821","id":"PMC_18550821","title":"The Coffin-Lowry syndrome-associated protein RSK2 is implicated in calcium-regulated exocytosis through the regulation of PLD1.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18550821","citation_count":42,"is_preprint":false},{"pmid":"21183680","id":"PMC_21183680","title":"Phosphorylation of caspase-8 (Thr-263) by ribosomal S6 kinase 2 (RSK2) mediates caspase-8 ubiquitination and stability.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21183680","citation_count":42,"is_preprint":false},{"pmid":"9920881","id":"PMC_9920881","title":"Transcription factor phosphorylation by pp90(rsk2). Identification of Fos kinase and NGFI-B kinase I as pp90(rsk2).","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9920881","citation_count":41,"is_preprint":false},{"pmid":"29279389","id":"PMC_29279389","title":"RSK2 drives cell motility by serine phosphorylation of LARG and activation of Rho GTPases.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29279389","citation_count":40,"is_preprint":false},{"pmid":"24336713","id":"PMC_24336713","title":"The Coffin-Lowry syndrome-associated protein RSK2 regulates neurite outgrowth through phosphorylation of phospholipase D1 (PLD1) and synthesis of phosphatidic acid.","date":"2013","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/24336713","citation_count":40,"is_preprint":false},{"pmid":"16879200","id":"PMC_16879200","title":"Identification of novel mutations in the RSK2 gene (RPS6KA3) in patients with Coffin-Lowry syndrome.","date":"2006","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16879200","citation_count":39,"is_preprint":false},{"pmid":"22918890","id":"PMC_22918890","title":"RSK2 as a key regulator in human skin cancer.","date":"2012","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/22918890","citation_count":39,"is_preprint":false},{"pmid":"21794960","id":"PMC_21794960","title":"Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors.","date":"2011","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21794960","citation_count":38,"is_preprint":false},{"pmid":"25192723","id":"PMC_25192723","title":"Myricetin exerts anti-proliferative, anti-invasive, and pro-apoptotic effects on esophageal carcinoma EC9706 and KYSE30 cells via RSK2.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25192723","citation_count":38,"is_preprint":false},{"pmid":"28013489","id":"PMC_28013489","title":"RSK2 and its binding partners in cell proliferation, transformation and cancer development.","date":"2016","source":"Archives of pharmacal research","url":"https://pubmed.ncbi.nlm.nih.gov/28013489","citation_count":37,"is_preprint":false},{"pmid":"16723234","id":"PMC_16723234","title":"Homology model of RSK2 N-terminal kinase domain, structure-based identification of novel RSK2 inhibitors, and preliminary common pharmacophore.","date":"2006","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16723234","citation_count":35,"is_preprint":false},{"pmid":"21224359","id":"PMC_21224359","title":"Phosphorylation of H2AX at Ser139 and a new phosphorylation site Ser16 by RSK2 decreases H2AX ubiquitination and inhibits cell transformation.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21224359","citation_count":35,"is_preprint":false},{"pmid":"17938253","id":"PMC_17938253","title":"Critical role for Rsk2 in T-lymphocyte activation.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17938253","citation_count":34,"is_preprint":false},{"pmid":"18156174","id":"PMC_18156174","title":"Epidermal growth factor stimulates RSK2 activation through activation of the MEK/ERK pathway and src-dependent tyrosine phosphorylation of RSK2 at Tyr-529.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18156174","citation_count":33,"is_preprint":false},{"pmid":"31018569","id":"PMC_31018569","title":"RSK2-Mediated ELK3 Activation Enhances Cell Transformation and Breast Cancer Cell Growth by Regulation of c-fos Promoter Activity.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31018569","citation_count":32,"is_preprint":false},{"pmid":"36516759","id":"PMC_36516759","title":"EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancer.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36516759","citation_count":31,"is_preprint":false},{"pmid":"23208494","id":"PMC_23208494","title":"MEK1-RSK2 contributes to Hedgehog signaling by stabilizing GLI2 transcription factor and inhibiting ubiquitination.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23208494","citation_count":30,"is_preprint":false},{"pmid":"11992250","id":"PMC_11992250","title":"Unusual splice-site mutations in the RSK2 gene and suggestion of genetic heterogeneity in Coffin-Lowry syndrome.","date":"2002","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11992250","citation_count":29,"is_preprint":false},{"pmid":"22218090","id":"PMC_22218090","title":"RSK2 signaling in medial habenula contributes to acute morphine analgesia.","date":"2012","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22218090","citation_count":29,"is_preprint":false},{"pmid":"24031026","id":"PMC_24031026","title":"Targeting of magnolin on ERKs inhibits Ras/ERKs/RSK2-signaling-mediated neoplastic cell transformation.","date":"2013","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/24031026","citation_count":29,"is_preprint":false},{"pmid":"23012246","id":"PMC_23012246","title":"RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma.","date":"2012","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/23012246","citation_count":29,"is_preprint":false},{"pmid":"7943043","id":"PMC_7943043","title":"Regional localisation of a non-specific X-linked mental retardation gene (MRX19) to Xp22.","date":"1994","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7943043","citation_count":28,"is_preprint":false},{"pmid":"28914261","id":"PMC_28914261","title":"RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.","date":"2017","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/28914261","citation_count":28,"is_preprint":false},{"pmid":"27041561","id":"PMC_27041561","title":"RSK2 signals through stathmin to promote microtubule dynamics and tumor metastasis.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27041561","citation_count":28,"is_preprint":false},{"pmid":"23608533","id":"PMC_23608533","title":"p90 RSK2 mediates antianoikis signals by both transcription-dependent and -independent mechanisms.","date":"2013","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23608533","citation_count":28,"is_preprint":false},{"pmid":"16723511","id":"PMC_16723511","title":"ERK1/2 regulates ANG II-dependent cell proliferation via cytoplasmic activation of RSK2 and nuclear activation of elk1.","date":"2006","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16723511","citation_count":27,"is_preprint":false},{"pmid":"27829215","id":"PMC_27829215","title":"RSK2 activity mediates glioblastoma invasiveness and is a potential target for new therapeutics.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27829215","citation_count":26,"is_preprint":false},{"pmid":"24141780","id":"PMC_24141780","title":"RSK2 regulates endocytosis of FGF receptor 1 by phosphorylation on serine 789.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24141780","citation_count":26,"is_preprint":false},{"pmid":"25855080","id":"PMC_25855080","title":"Regulation of NHE3 by lysophosphatidic acid is mediated by phosphorylation of NHE3 by RSK2.","date":"2015","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25855080","citation_count":26,"is_preprint":false},{"pmid":"10528858","id":"PMC_10528858","title":"Unreported RSK2 missense mutation in two male sibs with an unusually mild form of Coffin-Lowry syndrome.","date":"1999","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10528858","citation_count":25,"is_preprint":false},{"pmid":"14986828","id":"PMC_14986828","title":"Intronic L1 insertion and F268S, novel mutations in RPS6KA3 (RSK2) causing Coffin-Lowry syndrome.","date":"2003","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14986828","citation_count":24,"is_preprint":false},{"pmid":"17100996","id":"PMC_17100996","title":"Mutations in the RSK2(RPS6KA3) gene cause Coffin-Lowry syndrome and nonsyndromic X-linked mental retardation.","date":"2006","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17100996","citation_count":24,"is_preprint":false},{"pmid":"28439875","id":"PMC_28439875","title":"Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RPS6KA3 signalling axis in multiple myeloma.","date":"2017","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/28439875","citation_count":24,"is_preprint":false},{"pmid":"19129453","id":"PMC_19129453","title":"Mitogen-activated protein kinase-activated kinase RSK2 plays a role in innate immune responses to influenza virus infection.","date":"2009","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/19129453","citation_count":24,"is_preprint":false},{"pmid":"10934212","id":"PMC_10934212","title":"Cloning and characterization of Xenopus Rsk2, the predominant p90 Rsk isozyme in oocytes and eggs.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10934212","citation_count":23,"is_preprint":false},{"pmid":"30942462","id":"PMC_30942462","title":"Isobavachalcone exerts anti‑proliferative and pro‑apoptotic effects on human liver cancer cells by targeting the ERKs/RSK2 signaling pathway.","date":"2019","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/30942462","citation_count":23,"is_preprint":false},{"pmid":"30344937","id":"PMC_30344937","title":"Carnosol suppresses patient-derived gastric tumor growth by targeting RSK2.","date":"2018","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/30344937","citation_count":23,"is_preprint":false},{"pmid":"20969498","id":"PMC_20969498","title":"Targeting RSK2 in human malignancies.","date":"2010","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/20969498","citation_count":22,"is_preprint":false},{"pmid":"20832397","id":"PMC_20832397","title":"Coffin-Lowry syndrome: a role for RSK2 in mammalian neurogenesis.","date":"2010","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/20832397","citation_count":22,"is_preprint":false},{"pmid":"32919653","id":"PMC_32919653","title":"Microbial cell lysate supernatant (CLS) alteration impact on platinum nanoparticles fabrication, characterization, antioxidant and antibacterial activity.","date":"2020","source":"Materials science & engineering. C, Materials for biological applications","url":"https://pubmed.ncbi.nlm.nih.gov/32919653","citation_count":22,"is_preprint":false},{"pmid":"12711546","id":"PMC_12711546","title":"Expression pattern of the Rsk2, Rsk4 and Pdk1 genes during murine embryogenesis.","date":"2003","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/12711546","citation_count":21,"is_preprint":false},{"pmid":"11896450","id":"PMC_11896450","title":"X-linked Coffin-Lowry syndrome (CLS, MIM 303600, RPS6KA3 gene, protein product known under various names: pp90(rsk2), RSK2, ISPK, MAPKAP1).","date":"2002","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/11896450","citation_count":21,"is_preprint":false},{"pmid":"24055036","id":"PMC_24055036","title":"RSK2-induced stress tolerance enhances cell survival signals mediated by inhibition of GSK3β activity.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/24055036","citation_count":21,"is_preprint":false},{"pmid":"9134868","id":"PMC_9134868","title":"Complement Cls, a classical enzyme with novel functions at the endochondral ossification center: immunohistochemical staining of activated Cls with a neoantigen-specific antibody.","date":"1997","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/9134868","citation_count":21,"is_preprint":false},{"pmid":"17404396","id":"PMC_17404396","title":"Involvement of ERKs, RSK2 and PKR in UVA-induced signal transduction toward phosphorylation of eIF2alpha (Ser(51)).","date":"2007","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/17404396","citation_count":21,"is_preprint":false},{"pmid":"10094187","id":"PMC_10094187","title":"Novel mutations in Rsk-2, the gene for Coffin-Lowry syndrome (CLS).","date":"1999","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/10094187","citation_count":21,"is_preprint":false},{"pmid":"33069758","id":"PMC_33069758","title":"VGLL1 phosphorylation and activation promotes gastric cancer malignancy via TGF-β/ERK/RSK2 signaling.","date":"2020","source":"Biochimica et biophysica acta. Molecular cell research","url":"https://pubmed.ncbi.nlm.nih.gov/33069758","citation_count":20,"is_preprint":false},{"pmid":"32958832","id":"PMC_32958832","title":"RSK2 protects human breast cancer cells under endoplasmic reticulum stress through activating AMPKα2-mediated autophagy.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32958832","citation_count":20,"is_preprint":false},{"pmid":"37068088","id":"PMC_37068088","title":"The RSK2-RPS6 axis promotes axonal regeneration in the peripheral and central nervous systems.","date":"2023","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/37068088","citation_count":20,"is_preprint":false},{"pmid":"24416220","id":"PMC_24416220","title":"RSK2 is a modulator of craniofacial development.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24416220","citation_count":20,"is_preprint":false},{"pmid":"25414238","id":"PMC_25414238","title":"Rsk2 controls synovial fibroblast hyperplasia and the course of arthritis.","date":"2014","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/25414238","citation_count":20,"is_preprint":false},{"pmid":"36684450","id":"PMC_36684450","title":"RSK1 and RSK2 serine/threonine kinases regulate different transcription programs in cancer.","date":"2023","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/36684450","citation_count":19,"is_preprint":false},{"pmid":"25395420","id":"PMC_25395420","title":"RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2.","date":"2014","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25395420","citation_count":19,"is_preprint":false},{"pmid":"29563609","id":"PMC_29563609","title":"RSK2 is required for TRAF6 phosphorylation-mediated colon inflammation.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/29563609","citation_count":19,"is_preprint":false},{"pmid":"17663748","id":"PMC_17663748","title":"Contrasting roles of neuronal Msk1 and Rsk2 in Bad phosphorylation and feedback regulation of Erk signalling.","date":"2007","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17663748","citation_count":19,"is_preprint":false},{"pmid":"35801099","id":"PMC_35801099","title":"New Mutations in cls Lead to Daptomycin Resistance in a Clinical Vancomycin- and Daptomycin-Resistant Enterococcus faecium Strain.","date":"2022","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/35801099","citation_count":19,"is_preprint":false},{"pmid":"27082640","id":"PMC_27082640","title":"Downregulation of RSK2 influences the biological activities of human osteosarcoma cells through inactivating AKT/mTOR signaling pathways.","date":"2016","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27082640","citation_count":18,"is_preprint":false},{"pmid":"16691578","id":"PMC_16691578","title":"A novel RSK2 (RPS6KA3) gene mutation associated with abnormal brain MRI findings in a family with Coffin-Lowry syndrome.","date":"2006","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/16691578","citation_count":17,"is_preprint":false},{"pmid":"35964097","id":"PMC_35964097","title":"CD147 mediates epidermal malignant transformation through the RSK2/AP-1 pathway.","date":"2022","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/35964097","citation_count":17,"is_preprint":false},{"pmid":"29351904","id":"PMC_29351904","title":"ERα-Mediated Nuclear Sequestration of RSK2 Is Required for ER+ Breast Cancer Tumorigenesis.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29351904","citation_count":17,"is_preprint":false},{"pmid":"25044551","id":"PMC_25044551","title":"The historical Coffin-Lowry syndrome family revisited: identification of two novel mutations of RPS6KA3 in three male patients.","date":"2014","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/25044551","citation_count":17,"is_preprint":false},{"pmid":"23911878","id":"PMC_23911878","title":"IMP1 promotes choriocarcinoma cell migration and invasion through the novel effectors RSK2 and PPME1.","date":"2013","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23911878","citation_count":17,"is_preprint":false},{"pmid":"30377223","id":"PMC_30377223","title":"RSK2 contributes to myogenic vasoconstriction of resistance arteries by activating smooth muscle myosin and the Na+/H+ exchanger.","date":"2018","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/30377223","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51366,"output_tokens":11897,"usd":0.166276,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":22942,"output_tokens":5866,"usd":0.13068,"stage2_stop_reason":"end_turn"},"total_usd":0.296956,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"RSK2 (pp90RSK family) was purified, sequenced, and biochemically characterized as CREB kinase — the kinase that phosphorylates CREB at Ser-133 in response to growth factor-stimulated RAS-MAPK signaling, thereby coupling the RAS-MAPK pathway to immediate early gene transcription.\",\n      \"method\": \"Protein purification, sequencing, in vitro kinase assay, in vivo phosphorylation assay\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biochemical purification, sequencing, in vitro and in vivo kinase assays; replicated in multiple subsequent studies\",\n      \"pmids\": [\"8688081\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Mutations in RSK2 (Rsk-2 gene) cause Coffin-Lowry syndrome; missense mutations affecting sites critical for RSK2 function render the protein inactive in S6 kinase assays, establishing loss of kinase activity as the disease mechanism.\",\n      \"method\": \"Mutation screening, in vitro S6 kinase activity assay\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct enzymatic assay of mutant proteins, replicated across many subsequent mutation studies\",\n      \"pmids\": [\"8955270\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"RSK2 activity is specifically required for EGF-induced CREB Ser-133 phosphorylation and c-fos gene induction; CLS fibroblasts lacking functional RSK2 show dramatically attenuated EGF-stimulated CREB phosphorylation and c-fos expression, restored by wild-type RSK2 re-expression.\",\n      \"method\": \"Loss-of-function in CLS patient fibroblasts, transfection rescue, in vivo phosphorylation assay, reporter assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (patient cells, rescue, reporter assay), replicated by other labs\",\n      \"pmids\": [\"9770464\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"RSK2 is required for EGF-stimulated phosphorylation of histone H3; CLS patient fibroblasts and RSK2-knockout mouse ES cells fail to exhibit EGF-stimulated H3 phosphorylation, while mitotic H3 phosphorylation is unaffected; re-introduction of wild-type RSK2 restores EGF-stimulated H3 phosphorylation.\",\n      \"method\": \"Loss-of-function (CLS patient cells and homologous recombination knockout ES cells), rescue by wild-type RSK2 transfection\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout and patient-cell loss-of-function with rescue experiment, replicated independently\",\n      \"pmids\": [\"10436156\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"RSK2 (pp90rsk2) is identical to Fos kinase, which phosphorylates c-Fos at Ser-362 in a RAS/MEK-dependent manner; purified Fos kinase from NGF-stimulated PC12 cells was identified as pp90rsk2 by mass spectrometry and shown to be the same as NGFI-B kinase I. CREB kinase was distinguished as a distinct species from pp90rsk2.\",\n      \"method\": \"Affinity purification, mass spectrometry, in vitro kinase assay, chromatographic comparison\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — protein purification plus mass spectrometry identification plus kinase assays in a single rigorous study\",\n      \"pmids\": [\"9920881\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Phosphorylation of RSK2 at Ser386 in the hydrophobic motif (by the C-terminal kinase domain) creates a phosphoserine-dependent docking site that recruits PDK1, which then phosphorylates RSK2 at Ser227 (activating the N-terminal kinase domain); a S386K mutant showed no PDK1 interaction or Ser227 phosphorylation; a synthetic pSer386 peptide activated PDK1 6-fold in vitro.\",\n      \"method\": \"Co-immunoprecipitation, mutagenesis, in vitro kinase assay with synthetic peptide, in vivo phosphorylation assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted in vitro activation, mutagenesis, and in vivo validation in a single study\",\n      \"pmids\": [\"10856237\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Xenopus Rsk2 is the predominant p90Rsk isozyme (~120 nM) in oocytes/eggs, forms a heteromeric complex with p42 MAP kinase via sequences at the extreme C-terminus of Rsk2, and can be activated in vitro by p42 MAP kinase to a specific activity comparable to maximal in vivo activation.\",\n      \"method\": \"Protein quantification, co-immunoprecipitation, peptide competition, in vitro kinase reconstitution\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted in vitro activation and mechanistic domain mapping by peptide competition\",\n      \"pmids\": [\"10934212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"RSK2 and CBP form a complex in quiescent cells in which both RSK2 kinase activity and CBP HAT activity are inhibited; mitogenic stimulation causes dissociation dependent on RSK2 Ser227 phosphorylation, releasing both kinase and acetyltransferase activities.\",\n      \"method\": \"Co-immunoprecipitation, kinase activity assay, HAT activity assay, mutagenesis (Ser227)\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP, activity assays, and mutagenesis in a single study\",\n      \"pmids\": [\"11564891\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"RSK2 directly phosphorylates Bad at Ser112 in vitro, and RSK2-deficient CLS cells are defective for UVB-induced Bad Ser112 phosphorylation; phosphorylation of Bad at Ser112 by RSK2 (and JNK1/MSK1) promotes dissociation of Bad from Bcl-XL.\",\n      \"method\": \"In vitro kinase assay with active RSK2, RSK2-deficient CLS cells, dominant-negative mutants, co-immunoprecipitation (Bad/Bcl-XL)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay and genetic loss-of-function with mechanistic readout\",\n      \"pmids\": [\"11983683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PEA-15 binds directly to RSK2 (but not RSK1) via the C-terminus of PEA-15, co-precipitates in cells, blocks RSK2 nuclear accumulation after EGF stimulation, inhibits RSK2 kinase activity by ~50%, and suppresses RSK2-dependent CREB transcription and histone H3 phosphorylation.\",\n      \"method\": \"Co-immunoprecipitation from cells, in vitro pulldown with purified PEA-15 and in vitro translated RSK2, kinase assay, reporter assay, nuclear localization assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP, direct in vitro binding, kinase assay, functional reporter and localization studies in one report\",\n      \"pmids\": [\"12796492\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ATF4 is a direct substrate of RSK2; RSK2 phosphorylates ATF4 and is required for timely osteoblast differentiation, terminal osteoblast differentiation, osteoblast-specific gene expression, and posttranscriptional regulation of Type I collagen synthesis. ATF4 deficiency recapitulates the skeletal phenotype of CLS.\",\n      \"method\": \"In vitro kinase assay, genetic knockout mice (RSK2 and ATF4), osteoblast differentiation assays, gene expression analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro kinase assay plus two genetic knockouts with convergent phenotypes, published in Cell\",\n      \"pmids\": [\"15109498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"RSK2 phosphorylates c-Fos at Ser362, stabilizing c-Fos protein; loss of RSK2 leads to reduced c-Fos levels, decreased proliferation, and increased apoptosis of transformed osteoblasts, impairing c-Fos-dependent osteosarcoma formation in mice.\",\n      \"method\": \"RSK2 knockout mice, c-Fos phosphorylation site mutagenesis, osteosarcoma formation assay, apoptosis and proliferation assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with defined cellular phenotype and mutagenesis of phosphorylation site\",\n      \"pmids\": [\"15719069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"FGFR3 directly tyrosine-phosphorylates RSK2 at Y529, facilitating binding of inactive ERK to RSK2, which is required for ERK-dependent phosphorylation and activation of RSK2; inhibition of RSK2 by siRNA or FMK induces apoptosis in FGFR3-expressing t(4;14)-positive myeloma cells.\",\n      \"method\": \"Phospho-proteomics, in vitro kinase assay (FGFR3 + RSK2), co-immunoprecipitation, siRNA knockdown, apoptosis assay\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — phosphoproteomic identification, in vitro kinase assay, mechanistic co-IP, genetic KD with phenotype\",\n      \"pmids\": [\"17785202\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"RSK2 directly interacts with NFAT3 (via both N- and C-terminal kinase domains binding to NLS1/Ser-Pro/polyproline domains of NFAT3), phosphorylates NFAT3 in vitro (Km=3.559 μM), induces NFAT3 nuclear localization upon stimulation, and is required for skeletal muscle cell differentiation into myotubes.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, RSK2-/- cells, siRNA knockdown, myotube differentiation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with Km determination, genetic knockout, and siRNA with mechanistic phenotype\",\n      \"pmids\": [\"17213202\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PEA-15 acts as a scaffold that independently binds ERK and RSK2, increases ERK-RSK2 association in a concentration-dependent manner, enhances RSK2 activity and CREB-mediated transcription, and this scaffolding function is regulated by PEA-15 phosphorylation. PEA-15-null lymphocytes show impaired RSK2 activation rescued by exogenous PEA-15.\",\n      \"method\": \"Co-immunoprecipitation, kinase activity assay, reporter assay, PEA-15 knockout lymphocytes, rescue by exogenous PEA-15\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods including KO cells with rescue and mechanistic binding studies\",\n      \"pmids\": [\"18077417\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"EGF-stimulated RSK2 tyrosine phosphorylation at Tyr-529 is mediated by Src family kinases (Src and Fyn), not by EGFR directly; Src/Fyn phosphorylation of Y529 facilitates binding of inactive ERK to RSK2, required for ERK-dependent RSK2 activation; PP2 (Src inhibitor) attenuates EGF-dependent RSK2 activation and Y529 phosphorylation.\",\n      \"method\": \"Mass spectrometry identification, in vitro kinase assay (Src/Fyn + recombinant RSK2), GST-RSK2 reconstitution, mutagenesis (Y529F), Src inhibitor PP2\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with recombinant proteins, mass spectrometry, mutagenesis, and reconstitution\",\n      \"pmids\": [\"18156174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"RSK2 colocalizes with TIA-1 and PABP1 in stress granules in stressed cells; the RSK2 N-terminal kinase domain directly interacts with the prion-related domain of TIA-1; RSK2 sequestration in granules and TIA-1 sequestration are codependent. Upon mitogen stimulation, RSK2 is released from stress granules and translocates to the nucleus via a C-terminal nucleocytoplasmic shuttling sequence, dependent on TIA-1; nuclear RSK2 alone is sufficient to induce cyclin D1 and enhance proliferation.\",\n      \"method\": \"Colocalization (fluorescence microscopy), co-immunoprecipitation, domain mapping, siRNA knockdown, nuclear localization assay, cyclin D1 reporter\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods: colocalization, reciprocal co-IP, domain mapping, siRNA, and functional nuclear-localization experiment\",\n      \"pmids\": [\"18775331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"RSK2 physically interacts with and phosphorylates PLD1 at Thr-147 in the phox homology domain; expression of inactive RSK2 mutants or RSK2 knockdown dramatically impairs exocytotic response in chromaffin cells; phosphomimetic PLD1-T147 mutant fully restores secretion in RSK2-depleted cells, placing RSK2 upstream of PLD1 in calcium-regulated exocytosis.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, dominant-negative mutants, siRNA knockdown, phosphomimetic rescue, chromaffin cell exocytosis assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay, genetic loss-of-function with phosphomimetic rescue establishing RSK2→PLD1 Thr147 pathway\",\n      \"pmids\": [\"18550821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"FGFR3 interacts with RSK2 through residue W332 in the RSK2 linker region; this interaction is required for FGFR3-dependent phosphorylation of RSK2 at Y529 and Y707. Phosphorylation at Y707 contributes to RSK2 activation by disrupting the autoinhibitory αL-helix, while Y529 phosphorylation facilitates ERK binding.\",\n      \"method\": \"Co-immunoprecipitation, mutagenesis (W332, Y529, Y707), in vitro kinase assay, murine bone marrow transplant with RSK2-knockout cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis of multiple sites, in vitro kinase assay, and in vivo genetic model\",\n      \"pmids\": [\"19223461\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The RSK2 N-terminal kinase domain (NTD) is required for activation of the ERK-mediated C-terminal kinase domain (CTD); NTD plays a key role in substrate phosphorylation; Val82 and Lys100 in the NTD are critical for kaempferol binding and RSK2 activity, established by homology modeling, mutagenesis, and small-molecule docking.\",\n      \"method\": \"Mutagenesis (Val82, Lys100), homology model + docking validated by mutagenesis, kinase activity assay, domain deletion experiments\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — mutagenesis and kinase assays with computational validation, single lab\",\n      \"pmids\": [\"19435896\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RSK2 phosphorylates caspase-8 at Thr-263, promoting caspase-8 ubiquitination and proteasomal degradation in response to EGF; RSK2 thereby blocks Fas-induced apoptosis through phosphorylation of caspase-8.\",\n      \"method\": \"In vitro kinase assay, site-directed mutagenesis (Thr263), proteasome inhibition assay, Fas-induced apoptosis assay, RSK2 knockout cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro kinase assay and mutagenesis, single lab\",\n      \"pmids\": [\"21183680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ATF1 is a novel substrate of RSK2; RSK2 phosphorylates ATF1 at Ser-63, enhancing ATF1 transcriptional activity; eriodictyol binds the RSK2 NTD (confirmed by crystal structure docking and in vitro pulldown) and inhibits RSK2-mediated ATF1 phosphorylation.\",\n      \"method\": \"In vitro kinase assay, crystal structure-based docking, in vitro pulldown, cell-based phosphorylation assay, reporter assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro kinase assay with structural docking and pulldown confirmation, single lab\",\n      \"pmids\": [\"21098035\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"RSK2 directly phosphorylates histone H2AX at both Ser139 and a newly identified site Ser16; EGF-induced phosphorylation at both sites is decreased in RSK2 knockout cells; RSK2-mediated H2AX phosphorylation enhances H2AX stability and prevents EGF-induced cell transformation; RSK2 and DNA-PK (but not ATM/ATR) are required for Ser139 phosphorylation, while only RSK2 is required for Ser16 phosphorylation.\",\n      \"method\": \"In vitro kinase assay, RSK2 knockout cells, co-immunoprecipitation, immunofluorescence, cell transformation assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro kinase assay and knockout cells, single lab\",\n      \"pmids\": [\"21224359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"RSK2 mediates Ras/Raf-dependent inactivation of integrins: active RSK2 impairs cell adhesion and fibronectin matrix assembly, promotes cell motility, reduces actin stress fibers, disrupts focal adhesions, co-localizes with the integrin activator talin, promotes filamin phosphorylation and integrin binding, and is itself activated in response to fibronectin ligation.\",\n      \"method\": \"RSK2 siRNA knockdown, integrin activation assays, co-localization by immunofluorescence, fibronectin matrix assembly assay, migration assay, co-immunoprecipitation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — multiple functional assays and co-localization in single lab\",\n      \"pmids\": [\"23118220\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RSK2 phosphorylates PLD1 at Thr-147, activating PLD1 and promoting synthesis of phosphatidic acid at sites of neurite outgrowth; this RSK2→PLD1 pathway controls TiVAMP/VAMP-7 vesicle fusion and is required for NGF-induced neurite outgrowth; phosphomimetic PLD1 rescues neurite outgrowth in RSK2-silenced cells.\",\n      \"method\": \"RSK2 and PLD1 knockout mice neurons, siRNA, pharmacological inhibition, TIRF microscopy, phosphomimetic rescue in PC12 cells\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout neuronal model, pharmacological inhibition, TIRF microscopy, and phosphomimetic rescue with multiple orthogonal methods\",\n      \"pmids\": [\"24336713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RSK2-CREB signaling upregulates fascin-1 expression; RSK2 knockdown disrupts filopodia formation and bundling in invasive cancer cells; fascin-1 expression rescues the loss of invasion caused by RSK2 knockdown, establishing the RSK2→CREB→Fascin-1 axis in cancer cell invasion and metastasis.\",\n      \"method\": \"siRNA knockdown, RSK2 inhibitor (FMK-MEA), fascin-1 rescue expression, filopodia imaging, invasion assay, in vivo metastasis model\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — mechanistic rescue experiment with functional pathway placement, single lab\",\n      \"pmids\": [\"24085294\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RSK2 directly binds and phosphorylates stathmin at Ser16 at the leading edge of cancer cells, reducing stathmin-mediated microtubule depolymerization and promoting microtubule stability; phosphomimetic stathmin-S16D rescues the decreased invasive and metastatic potential caused by RSK2 knockdown.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, RSK2 siRNA knockdown, phosphomimetic rescue, invasion and metastasis assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — in vitro kinase assay, co-IP, and phosphomimetic rescue, single lab\",\n      \"pmids\": [\"27041561\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RSK2 inhibits apoptosis signal-regulating kinase 1 (ASK1) by phosphorylating Ser83, Thr1109, and Thr1326; phospho-T1109/T1326 inhibits ATP binding to ASK1, and phospho-S83 attenuates ASK1 substrate MKK6 binding; RSK2 also provides antianoikis protection via CREB-mediated upregulation of PTK6 and downregulation of ING3.\",\n      \"method\": \"In vitro kinase assay, mutagenesis, ATP-binding assay, substrate binding assay, RSK2 knockdown, anoikis assay, gene expression analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro kinase assay with mechanistic site mutagenesis, single lab\",\n      \"pmids\": [\"23608533\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RSK2 phosphorylates TRAF6 at Ser46, Ser47, and Ser48; this phosphorylation is required for TRAF6 K63 ubiquitination, which promotes downstream inflammation signaling (IKKα/β, p38, JNK); RSK2 knockout mice show reduced F4/80 and CD3 infiltration and reduced TRAF6 K63 ubiquitination in colon tissue.\",\n      \"method\": \"In vitro kinase assay, RSK2 knockout mice, co-immunoprecipitation, ubiquitination assay, colon inflammation model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Weak — in vitro kinase assay and genetic KO with in vivo readout, single lab\",\n      \"pmids\": [\"29563609\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RSK2 interacts with FGFR1, confirmed by yeast two-hybrid and in vitro/in vivo experiments; phosphorylated RSK2 phosphorylates Ser789 in the C-terminal tail of FGFR1; RSK2 inhibition leads to prolonged FGFR1 tyrosine transphosphorylation; mutation of Ser789 to Ala or RSK2 inhibition reduces FGFR1 endocytosis and ubiquitination, explaining prolonged signaling.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, in vitro kinase assay, site-directed mutagenesis (S789A), FGFR1 endocytosis assay, ubiquitination assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay, mutagenesis, and functional endocytosis assays with multiple orthogonal approaches in one study\",\n      \"pmids\": [\"24141780\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"RSK2 (but not RSK1) directly interacts with and phosphorylates NHE3 at Ser663 at the apical membrane domain, mediating LPA-induced NHE3 stimulation; Pyk2 maintains PDK1 autophosphorylation required for RSK2 activation upstream of NHE3.\",\n      \"method\": \"RSK2-specific siRNA knockdown, co-immunoprecipitation at apical membrane, in vitro phosphorylation assay, Ser663 mutagenesis, NHE3 transport activity assay\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — co-IP, mutagenesis, and transport assay in single lab\",\n      \"pmids\": [\"25855080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"β-Trcp ubiquitin ligase and RSK2 cooperate to degrade FOXN2; RSK2 phosphorylates FOXN2 at Ser365 and Ser369 in a conserved DSGYAS motif, targeting it for β-Trcp-mediated ubiquitination and proteasomal degradation, which promotes tumor growth and radioresistance in lung cancer.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, site-directed mutagenesis (Ser365, Ser369), ubiquitination assay, gain/loss-of-function studies\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro kinase assay and mutagenesis with functional readout, single lab\",\n      \"pmids\": [\"29396548\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"RSK2 directly interacts with leukemia-associated RhoGEF (LARG) and nucleotide-bound Rho isoforms (RhoA, RhoB, RhoC but not Rac1 or Cdc42); EGF/FBS stimulation induces association of endogenous RSK2 with LARG; RSK2 phosphorylates LARG at Ser1288 to activate RhoA; Thr577 phosphorylation on RSK2 is essential for this; RSK2-mediated motility requires RhoA and RhoB but not RhoC.\",\n      \"method\": \"Co-immunoprecipitation (endogenous), in vitro kinase assay, mutagenesis (Ser1288, Thr577), RhoA activity assay, migration/invasion assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — endogenous co-IP, in vitro kinase assay, multiple mutagenesis experiments, and functional motility assays\",\n      \"pmids\": [\"29279389\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"RSK2 phosphorylates the regulatory myosin light chain (RLC20) at Ser19 in vitro, promoting smooth muscle contractility; RSK2 also phosphorylates an activating site on NHE-1, causing cytosolic alkalinization and increased intracellular Ca2+ that promotes vasoconstriction; Rsk2-deficient mice show dilated resistance arteries, reduced myogenic tone, reduced RLC20 phosphorylation, suppressed NHE-1 activity, and lower blood pressure.\",\n      \"method\": \"In vitro kinase assay (RSK2 + RLC20), Rsk2 knockout mice (myogenic tone, blood pressure, pH and Ca2+ measurements), in situ phosphorylation analysis\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay identifying Ser19, multiple physiological readouts in genetic knockout mice\",\n      \"pmids\": [\"30377223\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ERα physically interacts with RSK2 through its N-terminus and sequesters active RSK2 into the nucleus, where it activates a proneoplastic transcriptional network; antiestrogens disrupt the RSK2–ERα interaction, driving RSK2 into the cytoplasm; transgenic mice with stable nuclear RSK2 in the mammary gland develop high-grade ductal carcinoma in situ.\",\n      \"method\": \"Co-immunoprecipitation, nuclear fractionation, transgenic mouse model, in vitro and in vivo breast cancer models\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, fractionation, transgenic mouse model, multiple in vitro and in vivo models in single study\",\n      \"pmids\": [\"29351904\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"RSK2 directly interacts with ELK3 through its N-terminal kinase and linker domains binding to the D and C domains of ELK3, phosphorylates ELK3, and enhances c-fos promoter activity via ELK3; RSK2 deficiency reduces ELK3 nuclear localization.\",\n      \"method\": \"Co-immunoprecipitation (domain mapping), kinase assay, reporter assay (c-fos promoter), immunocytofluorescence, RSK2 knockdown/knockout\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — co-IP with domain mapping and functional reporter, single lab\",\n      \"pmids\": [\"31018569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"RSK2-inactivating mutations in HCC attenuate a SOS1/2-dependent negative feedback loop, leading to activation of MAPK signaling; restoring RSK2 expression in RSK2-null HCC cells suppresses proliferation and migration in vitro and tumorigenicity in vivo.\",\n      \"method\": \"Exome sequencing, RSK2 re-expression in natural RSK2-null cells, RNA-seq, qRT-PCR, mass spectrometry, xenograft tumor model\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (RNA-seq, MS, in vitro and in vivo functional assays), single lab\",\n      \"pmids\": [\"32918955\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"RSK2 directly binds AMPKα2 in the nucleus and phosphorylates it at Thr172, promoting autophagy under ER stress; IRE1α (ER membrane UPR sensor) is required for ERK1/2-RSK2 activation under ER stress; suppression of RSK2-mediated autophagy enhances sensitivity to ER stress-inducing agents.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay (RSK2 + AMPKα2), IRE1α knockdown, RSK2 knockdown, autophagy assay, in vivo xenograft\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — co-IP and in vitro kinase assay, single lab\",\n      \"pmids\": [\"32958832\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TGF-β activates ERK and RSK2, causing nuclear translocation of phosphorylated RSK2, which then phosphorylates VGLL1 at Ser84; phosphorylated VGLL1 acts as a transcription cofactor of TEAD4, activating MMP9 transcription to promote gastric cancer malignancy.\",\n      \"method\": \"Site-directed mutagenesis (Ser84), co-immunoprecipitation, EMSA, ChIP assay, immunoprecipitation, reporter assay\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — mutagenesis, co-IP, ChIP, and functional assays, single lab\",\n      \"pmids\": [\"33069758\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GDH1 (phosphorylated by EGFR at Tyr135) and RSK2 cooperate to enhance CREB activity via CaMKIV signaling, promoting lung cancer metastasis; co-targeting RSK2 and GDH1 synergistically attenuates cancer cell invasion, anoikis resistance, and immune escape.\",\n      \"method\": \"siRNA knockdown, pharmacological inhibition, kinase assay, invasion/anoikis assay, CD8 T cell infiltration analysis, patient tumor correlation\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — functional genetic and pharmacological experiments with pathway mechanistic readouts, single lab\",\n      \"pmids\": [\"36516759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"RSK2 controls RPS6 phosphorylation in neurons, which is essential for peripheral and central nervous system axon regeneration; RSK2 controls the peripheral nerve preconditioning effect; the RSK2-RPS6 axis drives CNS regeneration in the dorsal column, synaptic plasticity, and target innervation leading to functional recovery.\",\n      \"method\": \"RSK2 knockout mice, in vivo axon injury/regeneration assay, DRG neuron culture, adeno-associated virus shRNA knockdown, electrophysiology\",\n      \"journal\": \"PLoS biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — genetic knockout with defined in vivo phenotype, single lab\",\n      \"pmids\": [\"37068088\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"RSK2 functions in the medial habenula to contribute to acute morphine analgesia; RSK2 knockout reduces acute morphine analgesia in the tail immersion test; AAV-mediated RSK2 knockdown specifically in the habenula recapitulates the reduced analgesia, suggesting a mu opioid receptor-RSK2 signaling mechanism in this brain region.\",\n      \"method\": \"RSK2 knockout mice, AAV-mediated shRNA knockdown in habenula, tail immersion test\",\n      \"journal\": \"Neuropsychopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout confirmed by region-specific knockdown with convergent phenotype\",\n      \"pmids\": [\"22218090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"RSK2 knockdown in cells enhances influenza virus polymerase activity and viral growth; RSK2 knockdown reduces NF-κB- and IFN-β-dependent promoter stimulation in response to influenza; RSK2 knockdown suppresses influenza-induced PKR phosphorylation, placing RSK2 upstream of PKR in the innate antiviral response.\",\n      \"method\": \"siRNA knockdown, viral polymerase activity assay, reporter assays (NF-κB, IFN-β), PKR phosphorylation assay\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — siRNA knockdown with multiple functional readouts, single lab\",\n      \"pmids\": [\"19129453\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"RSK2-deficient cells are defective for UV-induced STAT3 Ser727 phosphorylation, restored by ectopic RSK2 re-expression; active RSK2 induces phosphorylation of STAT3 immunoprecipitates in vitro, requiring a cofactor or downstream kinase; ATM is required upstream for UVA-stimulated RSK2 activation.\",\n      \"method\": \"RSK2-deficient cells, rescue by ectopic RSK2 expression, in vitro kinase assay on STAT3 immunoprecipitates, dominant-negative STAT3-β, reporter assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — indirect in vitro phosphorylation (requires cofactor, not direct reconstitution), single lab\",\n      \"pmids\": [\"12562765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RSK2 interacts with and phosphorylates GSK3β at Ser9, inhibiting GSK3β activity; RSK2-deficient MEFs show reduced GSK3β Ser9 phosphorylation upon EGF and calcium ionophore stimulation.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, RSK2 knockout MEFs, rescue by RSK2 re-expression\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single co-IP plus rescue, single lab\",\n      \"pmids\": [\"24055036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"RSK2 deficiency in TNF-α transgenic mice results in earlier and exacerbated arthritis with increased inflammatory cytokine production, MMP activity, and osteoclastogenic molecules; bone marrow from RSK2-null mice fails to transfer this phenotype, indicating RSK2 expression in mesenchymal (synovial fibroblast) cells controls synoviocyte hyperplasia and the course of arthritis.\",\n      \"method\": \"RSK2 knockout in TNFtg arthritis model, bone marrow transplant, in vitro FLS characterization, gene expression profiling\",\n      \"journal\": \"Annals of the rheumatic diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout crossed with disease model plus bone marrow transplant experiment to identify cell-type specificity\",\n      \"pmids\": [\"25414238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RSK2 knockdown in cortical radial precursors (by shRNA in vitro and in utero electroporation in vivo) decreases neurogenesis and increases the proportion of proliferating Pax6-positive radial precursor cells, establishing that RSK2 is required for cortical radial precursors to differentiate into neurons (but is not required for astrocyte generation).\",\n      \"method\": \"shRNA knockdown in primary cortical precursors, in utero electroporation, immunostaining for neuronal and progenitor markers\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo and in vitro genetic loss-of-function with distinct cellular phenotype\",\n      \"pmids\": [\"20832397\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RSK2 (RPS6KA3) is a dual-kinase-domain serine/threonine kinase activated downstream of ERK/MAPK: ERK phosphorylates the C-terminal kinase domain, which autophosphorylates Ser386 to create a PDK1-docking site, whereupon PDK1 phosphorylates Ser227 in the N-terminal kinase domain (the substrate-phosphorylating domain); Src/Fyn-mediated tyrosine phosphorylation at Y529 (and FGFR3 at Y707) additionally facilitates ERK recruitment; activated RSK2 phosphorylates a broad array of substrates including CREB (Ser133), histone H3, ATF4, ATF1, c-Fos (Ser362), ELK3, Bad (Ser112), caspase-8 (Thr263), H2AX (Ser16/Ser139), NFAT3, GSK3β (Ser9), ASK1 (Ser83/Thr1109/Thr1326), PLD1 (Thr147), stathmin (Ser16), LARG (Ser1288), TRAF6 (Ser46/47/48), NHE3 (Ser663), RLC20 (Ser19), AMPKα2 (Thr172), VGLL1 (Ser84), FGFR1 (Ser789), and FOXN2 (Ser365/369); it shuttles between cytoplasm (where it associates with TIA-1 in stress granules and with PEA-15 as a scaffold for ERK) and nucleus (where ERα can sequester it for transcriptional programs); through these substrates RSK2 controls gene transcription, chromatin remodeling, cell survival/apoptosis, exocytosis, integrin signaling, actin/microtubule dynamics, smooth muscle contractility, osteoblast differentiation, neurogenesis, and axon regeneration, and its loss-of-function causes Coffin-Lowry syndrome.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"RSK2 (RPS6KA3) is a serine/threonine kinase that couples the RAS–MAPK cascade to gene transcription, chromatin remodeling, cell survival, and cytoskeletal dynamics, originally identified as the growth factor-stimulated CREB kinase that phosphorylates CREB at Ser133 to drive immediate-early gene transcription [#0, #2]. Its activation is governed by a multi-step, dual-kinase-domain mechanism: the C-terminal kinase domain phosphorylates Ser386 to create a phosphoserine docking site that recruits and activates PDK1, which in turn phosphorylates Ser227 in the substrate-active N-terminal kinase domain [#5], while the N-terminal domain is itself required for activation of the ERK-controlled C-terminal domain [#19]; in oocytes RSK2 forms a heteromeric complex with p42 MAP kinase through its extreme C-terminus and is directly activatable by MAP kinase in vitro [#6]. Receptor tyrosine kinase and Src-family input tunes this circuit, as Src/Fyn phosphorylate Tyr529 and FGFR3 phosphorylates Tyr529/Tyr707 to facilitate ERK recruitment and relieve autoinhibition [#15, #18]. Through a broad substrate repertoire, RSK2 phosphorylates transcriptional and chromatin effectors (CREB, histone H3, c-Fos Ser362, ATF4) to control immediate-early transcription, c-Fos stability, osteoblast differentiation, and chromatin remodeling [#3, #4, #10, #11], promotes cell survival by phosphorylating Bad (Ser112), caspase-8 (Thr263), and ASK1 to block apoptosis and anoikis [#8, #20, #27], and regulates cytoskeletal and membrane dynamics by phosphorylating PLD1 (Thr147) for exocytosis and neurite outgrowth, stathmin (Ser16) and the RhoGEF LARG (Ser1288) for cell motility, and RLC20 (Ser19) with NHE-1 for smooth muscle contractility and blood pressure control [#17, #24, #26, #32, #33]. RSK2 localization is dynamically controlled: it is sequestered in cytoplasmic stress granules via TIA-1 binding and released upon mitogen stimulation to shuttle into the nucleus where it drives cyclin D1 and proliferation, a function modulated by the scaffold PEA-15 and by ERα-mediated nuclear retention [#16, #14, #34]. Loss-of-function mutations in RSK2 that abolish its kinase activity cause Coffin-Lowry syndrome [#1].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Establishing RSK2's core function and disease relevance: it was defined as the growth factor-activated CREB kinase that links RAS-MAPK signaling to transcription, and concurrently shown to cause Coffin-Lowry syndrome through loss of kinase activity.\",\n      \"evidence\": \"Protein purification, sequencing, and in vitro/in vivo kinase assays; mutation screening with S6 kinase activity assay of mutant proteins\",\n      \"pmids\": [\"8688081\", \"8955270\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the upstream activation steps beyond MAPK\", \"Did not establish which substrates mediate the disease phenotype\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Patient-cell loss-of-function with rescue confirmed RSK2 is specifically required for EGF-induced CREB Ser133 phosphorylation and c-fos induction, tying the kinase to a defined transcriptional output.\",\n      \"evidence\": \"CLS patient fibroblast loss-of-function, transfection rescue, in vivo phosphorylation and reporter assays\",\n      \"pmids\": [\"9770464\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address other RSK2-dependent transcription factors\", \"Did not map the activation hierarchy\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Genetic knockout and patient-cell studies extended RSK2's reach to chromatin, showing it mediates EGF-stimulated (but not mitotic) histone H3 phosphorylation, and identified it as the c-Fos kinase phosphorylating Ser362.\",\n      \"evidence\": \"CLS patient cells and knockout ES cells with rescue; affinity purification, mass spectrometry, and in vitro kinase assays\",\n      \"pmids\": [\"10436156\", \"9920881\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish whether H3 phosphorylation is direct or via an intermediate kinase\", \"Did not resolve overlap between CREB kinase and Fos kinase identities\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Reconstituted biochemistry solved the activation mechanism: Ser386 phosphorylation creates a PDK1 docking site driving Ser227 phosphorylation, and RSK2 forms a stable MAP kinase complex via its C-terminus.\",\n      \"evidence\": \"Co-IP, mutagenesis, in vitro kinase assays with synthetic phosphopeptide, peptide competition, and in vitro reconstitution\",\n      \"pmids\": [\"10856237\", \"10934212\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address tyrosine-phosphorylation inputs\", \"Did not resolve the role of the N-terminal domain in CTD activation\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"RSK2 activity was coupled to coactivator control, showing it forms a mutually inhibitory complex with CBP that dissociates upon Ser227-dependent activation to release both kinase and HAT activities.\",\n      \"evidence\": \"Reciprocal co-IP, kinase and HAT activity assays, Ser227 mutagenesis\",\n      \"pmids\": [\"11564891\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the binding interface\", \"Did not establish in vivo transcriptional consequences\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identification of PEA-15 as a direct, RSK2-selective binding partner revealed spatial regulation: it blocks RSK2 nuclear accumulation and dampens its kinase and transcriptional output.\",\n      \"evidence\": \"Co-IP, in vitro pulldown, kinase, reporter, and nuclear localization assays\",\n      \"pmids\": [\"12796492\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not yet establish the scaffolding mechanism on ERK\", \"Did not address physiological relevance in tissues\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Genetic dissection linked RSK2 to skeletal biology through ATF4 phosphorylation, explaining the CLS bone phenotype via osteoblast differentiation and collagen synthesis.\",\n      \"evidence\": \"In vitro kinase assay, RSK2 and ATF4 knockout mice, osteoblast differentiation and gene expression assays\",\n      \"pmids\": [\"15109498\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not map the ATF4 phosphosite\", \"Did not address other skeletal substrates\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"RSK2 was shown to stabilize c-Fos via Ser362 phosphorylation, defining a pro-tumorigenic role in osteosarcoma cell survival and proliferation.\",\n      \"evidence\": \"RSK2 knockout mice, c-Fos phosphosite mutagenesis, osteosarcoma formation and apoptosis/proliferation assays\",\n      \"pmids\": [\"15719069\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address human tumor relevance\", \"Did not define degradation machinery for unphosphorylated c-Fos\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Tyrosine-kinase inputs and scaffolding were defined: Src/Fyn and FGFR3 phosphorylate Tyr529 to promote ERK binding and RSK2 activation, and PEA-15 was shown to scaffold ERK-RSK2 association, while RSK2 was also placed in calcium signaling via NFAT3.\",\n      \"evidence\": \"Phosphoproteomics, in vitro kinase assays, co-IP, mutagenesis, Src inhibitor, knockout/knockdown cells, and rescue\",\n      \"pmids\": [\"17785202\", \"18156174\", \"18077417\", \"17213202\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish the full structural basis of ERK recruitment\", \"Did not resolve relative contributions of Src vs FGFR3 in different cell types\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Subcellular trafficking was resolved: RSK2 is sequestered in stress granules through TIA-1 binding and released upon mitogen stimulation to enter the nucleus and drive cyclin D1 and proliferation; RSK2 was also linked to regulated exocytosis via PLD1 Thr147.\",\n      \"evidence\": \"Colocalization, co-IP, domain mapping, siRNA, nuclear localization and cyclin D1 reporter assays; in vitro kinase, phosphomimetic rescue in chromaffin cells\",\n      \"pmids\": [\"18775331\", \"18550821\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the shuttling signal at residue level\", \"Did not establish which nuclear substrates drive cyclin D1\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"FGFR3 docking and intramolecular activation logic were refined: FGFR3 binds the RSK2 linker (W332) to phosphorylate Tyr529/Tyr707, and the N-terminal domain was shown to be required for activation of the ERK-driven C-terminal domain.\",\n      \"evidence\": \"Co-IP, multi-site mutagenesis, in vitro kinase assay, bone marrow transplant; homology modeling/docking validated by mutagenesis\",\n      \"pmids\": [\"19223461\", \"19435896\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"NTD activation model rests on a single lab with computational validation\", \"Did not resolve the autoinhibitory αL-helix structure experimentally\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"RSK2's anti-apoptotic and genome-protective substrate set expanded to caspase-8 (Thr263, promoting degradation) and histone H2AX (Ser16/Ser139, enhancing stability), implicating it in survival and transformation control.\",\n      \"evidence\": \"In vitro kinase assays, site mutagenesis, knockout cells, proteasome and apoptosis/transformation assays\",\n      \"pmids\": [\"21183680\", \"21224359\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Each rests on single-lab evidence\", \"Did not establish reciprocal regulation in tissue contexts\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"A coherent cytoskeletal/motility program emerged: RSK2 inactivates integrins, phosphorylates stathmin (Ser16) and LARG (Ser1288) to control microtubules and RhoA, drives PLD1-dependent neurite outgrowth, suppresses ASK1, and upregulates fascin-1 via CREB, while also phosphorylating FGFR1 (Ser789) to control receptor endocytosis.\",\n      \"evidence\": \"Co-IP, in vitro kinase assays, siRNA/knockout, phosphomimetic rescue, migration/invasion/endocytosis assays, knockout neuron models with TIRF\",\n      \"pmids\": [\"23118220\", \"24336713\", \"24085294\", \"27041561\", \"23608533\", \"24141780\", \"29279389\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Most substrate links derive from individual labs\", \"Did not integrate competing motility substrates into one quantitative model\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Physiological and oncogenic roles were extended in vivo: RSK2 drives smooth muscle contractility (RLC20 Ser19, NHE-1) and blood pressure, and ERα-mediated nuclear sequestration of RSK2 promotes a proneoplastic transcriptional network in breast tissue.\",\n      \"evidence\": \"In vitro kinase assay, Rsk2 knockout mice with physiological readouts; co-IP, fractionation, transgenic mouse breast cancer model\",\n      \"pmids\": [\"30377223\", \"29351904\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"ERα-RSK2 axis rests on a single study\", \"Did not define the full nuclear transcriptional targets\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"RSK2 was placed in stress-response and feedback circuits: it phosphorylates AMPKα2 (Thr172) to promote ER-stress autophagy and VGLL1 (Ser84) to drive TEAD4/MMP9 transcription, while RSK2-inactivating mutations relieve SOS1/2 feedback to activate MAPK in liver cancer.\",\n      \"evidence\": \"Co-IP, in vitro kinase assays, knockdown, autophagy assays; ChIP/EMSA/reporter; exome sequencing, RNA-seq, MS, xenografts\",\n      \"pmids\": [\"32958832\", \"33069758\", \"32918955\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Context-dependent tumor-promoting vs tumor-suppressive roles remain unreconciled\", \"Each mechanism rests on single-lab evidence\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"RSK2 was established as a driver of axon regeneration via control of RPS6 phosphorylation, completing a neuronal role spanning neurogenesis, opioid analgesia, and regeneration.\",\n      \"evidence\": \"RSK2 knockout mice, in vivo axon injury/regeneration assays, DRG culture, AAV shRNA, electrophysiology\",\n      \"pmids\": [\"37068088\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not define whether RPS6 phosphorylation is direct\", \"Did not link the neuronal phenotype to CLS cognitive features\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How RSK2's broad substrate selection is spatially and temporally partitioned across competing transcriptional, survival, and cytoskeletal programs in a given cell remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying framework reconciling tumor-suppressive (HCC) versus oncogenic (breast, lung, gastric) roles\", \"No structural model of the full activated dual-kinase-domain holoenzyme with bound partners\", \"Substrate prioritization mechanisms under different stimuli are uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 5, 8, 10, 17, 26, 32, 33]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 5, 8, 17, 27]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [3, 22]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 4, 35]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [9, 16]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [9, 16, 34, 37]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [23, 30]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 5, 15, 18, 32]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 2, 4, 10, 38]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [8, 20, 27]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [3, 22]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [37]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"PDK1\", \"MAPK1\", \"PEA15\", \"TIA1\", \"FGFR3\", \"CREBBP\", \"LARG\", \"ESR1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}